{"ctNumber":"2024-515909-26-00","ctStatus":"Authorised","startDateEU":"2022-01-26","decisionDate":"2024-10-30T11:32:56.31","publishDate":"2026-08-12T03:41:34.439919557","ctPublicStatusCode":5,"authorizedApplication":{"authorizedPartI":{"id":139956,"rowSubjectCount":135,"rowCountriesInfo":[{"eutctId":100000000429,"name":"Israel","isoNumber":376,"isoAlpha2Code":"IL","isoAlpha3Code":"ISR","current":true},{"eutctId":100000000329,"name":"Australia","isoNumber":36,"isoAlpha2Code":"AU","isoAlpha3Code":"AUS","current":true},{"eutctId":100000000439,"name":"Korea, Republic of","isoNumber":410,"isoAlpha2Code":"KR","isoAlpha3Code":"KOR","current":true},{"eutctId":100000000556,"name":"United Kingdom","isoNumber":826,"isoAlpha2Code":"GB","isoAlpha3Code":"GBR","current":true},{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true}],"products":[{"id":583263,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11591074","productPharmForm":"CAPSULE","euMpNumber":"PRD11584202","prodAuthStatus":1,"prodName":"AL102","pharmForm":"CAPSULE","sponsorProductCode":"AL102","activeSubstanceName":"VAREGACESTAT","euSubstNumber":"SUB218539","nameOrg":"IMMUNOME INC","productSubstances":[{"productPk":"11591074","substancePk":"404769","nameOrg":"IMMUNOME INC","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"VAREGACESTAT","substanceEvCode":"SUB218539","synonyms":["BMS-986115","(2R,3S)-N1-[(3S)-5-(3-Fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide","AL102"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1.2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"999","maxTreatmentPeriod":999,"timeUnitCode":"1","otherMedicinalProduct":"Chemical","evCode":"PRD11584202","sponsorProductCodeEdit":"AL102","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"AL102","jsonActiveSubstanceNames":"varegacestat","pharmaceuticalFormDisplay":"CAPSULE"},{"id":583264,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Placebo capsule","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Placebo capsule","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"},{"id":583262,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11591075","productPharmForm":"CAPSULE","euMpNumber":"PRD11584484","prodAuthStatus":1,"prodName":"AL102","pharmForm":"CAPSULE","sponsorProductCode":"AL102","activeSubstanceName":"VAREGACESTAT","euSubstNumber":"SUB218539","nameOrg":"IMMUNOME INC","productSubstances":[{"productPk":"11591075","substancePk":"404769","nameOrg":"IMMUNOME INC","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"VAREGACESTAT","substanceEvCode":"SUB218539","synonyms":["BMS-986115","(2R,3S)-N1-[(3S)-5-(3-Fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide","AL102"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"4","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"999","maxTreatmentPeriod":999,"timeUnitCode":"1","otherMedicinalProduct":"Chemical","evCode":"PRD11584484","sponsorProductCodeEdit":"AL102","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"AL102","jsonActiveSubstanceNames":"varegacestat","pharmaceuticalFormDisplay":"CAPSULE"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors","fullTitleTranslations":[{"id":11815936,"uuid":"71ef91b1-0624-44aa-9f8e-4c087b9a4f8e","attributeTranslation":"RINGSIDE: Estudio en fase II/III, aleatorizado y multicéntrico para evaluar AL102 en pacientes con tumores desmoides en progresión.","language":7,"languageDescription":"Spanish"},{"id":11815934,"uuid":"71ef91b1-0624-44aa-9f8e-4c087b9a4f8e","attributeTranslation":"RINGSIDE: Randomizowane, wieloośrodkowe badanie fazy II/III prowadzone w celu oceny produktu AL102 u pacjentów z guzami desmoidalnymi ulegającymi progresji","language":19,"languageDescription":"Polish"},{"id":11815935,"uuid":"71ef91b1-0624-44aa-9f8e-4c087b9a4f8e","attributeTranslation":"RINGSIDE: Een gerandomiseerd, fase 2/3-onderzoek in meerdere onderzoeksentra om AL102 te evalueren bij patiënten met progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"}],"publicTitle":"A study of AL102 in Progressing Desmoid Tumors","publicTitleTranslations":[{"id":11816000,"uuid":"6de1b27c-fdad-4a33-9b60-f652ee30537d","attributeTranslation":"Een onderzoek naar AL102 bij progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816001,"uuid":"6de1b27c-fdad-4a33-9b60-f652ee30537d","attributeTranslation":"Badanie oceniające AL102 w leczeniu guzów desmoidalnych ulegających progresji","language":19,"languageDescription":"Polish"},{"id":11816002,"uuid":"6de1b27c-fdad-4a33-9b60-f652ee30537d","attributeTranslation":"Estudio de AL102 en tumores desmoides en progresión.","language":7,"languageDescription":"Spanish"}],"shortTitle":"AL-DES-01","secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"10","trialCategory":"2","justificationForTrialCategory":"This is a phase II/III trial, therefore it falls under category 2","trialCategoryId":129336},"medicalCondition":{"partIMedicalConditions":[{"id":146571,"medicalCondition":"Progressing desmoid tumors","medicalConditionTranslations":[{"id":11815802,"uuid":"38540a31-342c-4a3b-aa1f-51802a4dc968","attributeTranslation":"Tumores desmoides en progresión","language":7,"languageDescription":"Spanish"},{"id":11815803,"uuid":"38540a31-342c-4a3b-aa1f-51802a4dc968","attributeTranslation":"Guzy desmoidalne ulegające progresji","language":19,"languageDescription":"Polish"},{"id":11815804,"uuid":"38540a31-342c-4a3b-aa1f-51802a4dc968","attributeTranslation":"Progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"}],"isConditionRareDisease":true}],"meddraConditionTerms":[{"termId":100000018969,"version":"20.1","level":"PT","termName":"Desmoid tumour","classificationCode":"10059352","organClass":100000004864,"active":false}]},"trialObjective":{"trialScopes":[{"code":"7","trialScopeId":425397},{"code":"5","trialScopeId":425396},{"code":"6","trialScopeId":425399},{"code":"4","trialScopeId":425398},{"code":"3","trialScopeId":425400},{"code":"13","otherDescription":"Food effect","trialScopeId":425401}],"mainObjective":"Part A (Phase II): To evaluate the safety and tolerability of AL102 in subjects with progressing desmoid tumors\nPart B (Phase III): To evaluate effects of AL102 on disease progression in subjects with progressing desmoid tumors\nOLE: To evaluate the safety and tolerability of AL102 in subjects with progressive desmoid tumors","mainObjectiveTranslations":[{"id":11815998,"uuid":"3dae89a4-8249-426f-923f-3d57095056d0","attributeTranslation":"Parte A: evaluar la seguridad y la tolerabilidad del AL102 en participantes con tumores desmoides en progresión.\nParte B: evaluar los efectos del AL102 sobre la progresión de la enfermedad en participantes con tumores desmoides en progresión.\nEA: evaluar la seguridad y la tolerabilidad del AL102 en participantes con tumores desmoides progresivos.","language":7,"languageDescription":"Spanish"},{"id":11815997,"uuid":"3dae89a4-8249-426f-923f-3d57095056d0","attributeTranslation":"Deel A: Evalueren van de veiligheid en verdraagbaarheid van AL102 bij onderzoeksdeelnemers met progressieve desmoïde tumoren\nDeel B: Evalueren van de effecten van AL102 op ziekteprogressie bij onderzoeksdeelnemers met progressieve desmoïde tumoren\nOLE: Evalueren van de veiligheid en verdraagbaarheid van AL102 bij onderzoeksdeelnemers met progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815999,"uuid":"3dae89a4-8249-426f-923f-3d57095056d0","attributeTranslation":"Część A: Ocena bezpieczeństwa stosowania i tolerancji AL102 u uczestników z guzami desmoidalnymi ulegającymi progresji\nCzęść B: Ocena wpływu AL102 na progresję choroby u uczestników z guzami desmoidalnymi ulegającymi progresji\nOkres kontynuacyjny prowadzony metodą otwartej próby \n(ang. Open Label Extension, OLE): Ocena bezpieczeństwa i tolerancji AL102 u uczestników z guzami desmoidalnymi ulegającymi progresji","language":19,"languageDescription":"Polish"}],"secondaryObjectives":[{"id":500140,"number":1,"secondaryObjective":"Part A: To assess the effects of AL102 on desmoid tumor size in subjects with progressing desmoid tumors","secondaryObjectiveTranslations":[{"id":11816004,"uuid":"edd24cca-e971-4d81-9637-15e1b6f38858","attributeTranslation":"Deel A: Beoordelen van de effecten van AL102 op de grootte van desmoïde tumoren bij onderzoeksdeelnemers met progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816003,"uuid":"edd24cca-e971-4d81-9637-15e1b6f38858","attributeTranslation":"Część A: Ocena wpływu AL102 na rozmiar guza desmoidalnego u uczestników z guzami desmoidalnymi ulegającymi progresji","language":19,"languageDescription":"Polish"},{"id":11816005,"uuid":"edd24cca-e971-4d81-9637-15e1b6f38858","attributeTranslation":"Parte A: evaluar los efectos del AL102 sobre el tamaño del tumor desmoide en participantes con tumores desmoides en progresión","language":7,"languageDescription":"Spanish"}]},{"id":500141,"number":2,"secondaryObjective":"Part B: To evaluate additional effects of AL102 on tumor response","secondaryObjectiveTranslations":[{"id":11816008,"uuid":"971e5a3d-5237-424f-ba7e-7d9dd7a36d5f","attributeTranslation":"Parte B: evaluar los efectos adicionales del AL102 en la respuesta tumoral.","language":7,"languageDescription":"Spanish"},{"id":11816007,"uuid":"971e5a3d-5237-424f-ba7e-7d9dd7a36d5f","attributeTranslation":"Deel B: Evalueren van bijkomende effecten van AL102 op de tumorrespons","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816006,"uuid":"971e5a3d-5237-424f-ba7e-7d9dd7a36d5f","attributeTranslation":"Część B: Ocena dodatkowego wpływu AL102 na odpowiedź guza","language":19,"languageDescription":"Polish"}]},{"id":500142,"number":3,"secondaryObjective":"Part B: To evaluate effects of AL102 on quality of life;","secondaryObjectiveTranslations":[{"id":11816009,"uuid":"ec802878-2534-488b-96ee-d100513713ca","attributeTranslation":"Deel B: Evalueren van de effecten van AL102 op de kwaliteit van leven","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816011,"uuid":"ec802878-2534-488b-96ee-d100513713ca","attributeTranslation":"Parte B: evaluar los efectos del AL102 en la calidad de vida.","language":7,"languageDescription":"Spanish"},{"id":11816010,"uuid":"ec802878-2534-488b-96ee-d100513713ca","attributeTranslation":"Część B: Ocena wpływu AL102 na jakość życia.","language":19,"languageDescription":"Polish"}]},{"id":500143,"number":4,"secondaryObjective":"Part B: To evaluate the safety and tolerability of AL102 in subjects with progressing desmoid tumors","secondaryObjectiveTranslations":[{"id":11816014,"uuid":"7f1cc1ce-699b-4d6e-a0dc-5d94c3c8c2b2","attributeTranslation":"Deel B: Evalueren van de veiligheid en verdraagbaarheid van AL102 bij onderzoeksdeelnemers met progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816013,"uuid":"7f1cc1ce-699b-4d6e-a0dc-5d94c3c8c2b2","attributeTranslation":"Parte B: evaluar la seguridad y la tolerabilidad del AL102 en participantes con tumores desmoides en progresión.","language":7,"languageDescription":"Spanish"},{"id":11816012,"uuid":"7f1cc1ce-699b-4d6e-a0dc-5d94c3c8c2b2","attributeTranslation":"Część B: Ocena bezpieczeństwa stosowania i tolerancji AL102 u uczestników z guzami desmoidalnymi ulegającymi progresji","language":19,"languageDescription":"Polish"}]},{"id":500144,"number":5,"secondaryObjective":"OLE: To evaluate the efficacy of AL102 in subjects with progressive desmoid tumors","secondaryObjectiveTranslations":[{"id":11816017,"uuid":"8ee8849d-54fd-4eae-9d0c-a68aa706d68a","attributeTranslation":"EA: evaluar la eficacia del AL102 en participantes con tumores desmoides progresivos.","language":7,"languageDescription":"Spanish"},{"id":11816015,"uuid":"8ee8849d-54fd-4eae-9d0c-a68aa706d68a","attributeTranslation":"OLE: Evalueren van de werkzaamheid van AL102 bij onderzoeksdeelnemers met progressieve desmoïde tumoren","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816016,"uuid":"8ee8849d-54fd-4eae-9d0c-a68aa706d68a","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Ocena skuteczności AL102 u uczestników z guzami desmoidalnymi ulegającymi progresji","language":19,"languageDescription":"Polish"}]},{"id":500145,"number":6,"secondaryObjective":"OLE: To evaluate effects of AL102 on quality of life","secondaryObjectiveTranslations":[{"id":11816020,"uuid":"495ebc97-5714-45f9-a644-6ed46d42b736","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Ocena wpływu AL102 na jakość życia","language":19,"languageDescription":"Polish"},{"id":11816019,"uuid":"495ebc97-5714-45f9-a644-6ed46d42b736","attributeTranslation":"OLE: Evalueren van de effecten van AL102 op de kwaliteit van leven","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11816018,"uuid":"495ebc97-5714-45f9-a644-6ed46d42b736","attributeTranslation":"EA: evaluar los efectos del AL102 en la calidad de vida.","language":7,"languageDescription":"Spanish"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":952404,"number":1,"principalInclusionCriteria":"Part A: At least 18 years of age (inclusive) at the time of signing the ICF","principalInclusionCriteriaTranslations":[{"id":11815938,"uuid":"474d905c-00f9-480a-8b3d-cf97ed69ca2e","attributeTranslation":"Część A: Wiek co najmniej 18 lat (włącznie) w momencie podpisania formularza świadomej zgody","language":19,"languageDescription":"Polish"},{"id":11815937,"uuid":"474d905c-00f9-480a-8b3d-cf97ed69ca2e","attributeTranslation":"Parte A: tener al menos 18 años de edad (inclusive) en el momento de firmar el FCI.","language":7,"languageDescription":"Spanish"},{"id":11815939,"uuid":"474d905c-00f9-480a-8b3d-cf97ed69ca2e","attributeTranslation":"Deel A: Ten minste 18 jaar of ouder op het moment van ondertekening van het informatie- en toestemmingsformulier","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952405,"number":10,"principalInclusionCriteria":"Part B: Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed per RECIST v1.1 (≥20% or new lesion) by investigator within 12 months of the screening visit scan.","principalInclusionCriteriaTranslations":[{"id":11815941,"uuid":"eb66af00-c0da-48bd-8503-bf67838e5c55","attributeTranslation":"Deel B: Histologisch bevestigde desmoïde tumor (agressieve fibromatose) door een plaatselijke patholoog (voorafgaand aan geïnformeerde toestemming), waarvan de onderzoeker heeft vastgesteld dat deze progressie vertoont volgens RECIST v1.1 (≥ 20% of nieuwe laesie) binnen 12 maanden na de scan bij het keuringsbezoek.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815940,"uuid":"eb66af00-c0da-48bd-8503-bf67838e5c55","attributeTranslation":"Parte B: tumor desmoide confirmado histológicamente (fibromatosis agresiva) por parte del anatomopatólogo local (antes del consentimiento informado) que haya progresado según los criterios RECIST v1.1 (≥20 % o lesión nueva) evaluado por el investigador en los 12 meses anteriores a la exploración de la visita de selección.","language":7,"languageDescription":"Spanish"},{"id":11815942,"uuid":"eb66af00-c0da-48bd-8503-bf67838e5c55","attributeTranslation":"Część B: Histologiczne potwierdzenie guza desmoidalnego (agresywna włókniakowatość) przez miejscowego patomorfologa (przed udzieleniem świadomej zgody), który uległ progresji zgodnie z kryteriami oceny odpowiedzi w guzach litych (ang. Response Evaluation Criteria in Solid Tumors, RECIST) w wersji 1.1 (wzrost o ≥20% lub nowa zmiana) w opinii badacza w ciągu 12 miesięcy od przesiewowego badania obrazowego","language":19,"languageDescription":"Polish"}]},{"id":952406,"number":11,"principalInclusionCriteria":"Part B: Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1","principalInclusionCriteriaTranslations":[{"id":11815943,"uuid":"344d38a5-d6eb-4bb8-8155-a4e7dfefdb53","attributeTranslation":"Parte B: datos sugestivos de enfermedad medible mediante TC o RM. Las lesiones medibles se definen según RECIST v1.1.","language":7,"languageDescription":"Spanish"},{"id":11815944,"uuid":"344d38a5-d6eb-4bb8-8155-a4e7dfefdb53","attributeTranslation":"Deel B: Bewijs van meetbare ziekte door CT/MRI-scan. Meetbare laesies worden gedefinieerd volgens RECIST v1.1","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815945,"uuid":"344d38a5-d6eb-4bb8-8155-a4e7dfefdb53","attributeTranslation":"Część B: Dowody na występowanie choroby mierzalnej w badaniu TK/RM. Mierzalne zmiany są definiowane według kryteriów RECIST w wersji 1.1","language":19,"languageDescription":"Polish"}]},{"id":952407,"number":12,"principalInclusionCriteria":"Part B: One of the following: • Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy); OR • Treatment naïve subjects for whom, in the opinion of the investigator, surgery or radiation therapy is not deemed appropriate;","principalInclusionCriteriaTranslations":[{"id":11815948,"uuid":"fe1093ac-c899-4401-862c-ec26c05c8348","attributeTranslation":"Część B: Spełnienie jednego z poniższych warunków:\n• Choroba nawrotowa/oporna na leczenie po zastosowaniu co najmniej jednego rzutu leczenia (w tym zabiegu chirurgicznego, radioterapii lub leczenia ogólnoustrojowego); LUB\n• Nieleczeni wcześniej uczestnicy, w przypadku których, w opinii badacza, zabieg chirurgiczny lub radioterapia nie są uważane za właściwe;","language":19,"languageDescription":"Polish"},{"id":11815946,"uuid":"fe1093ac-c899-4401-862c-ec26c05c8348","attributeTranslation":"Deel B: Een van de volgende:\n• Recidiverende/refractaire ziekte na ten minste één therapielijn (waaronder chirurgie, bestraling of systemische therapie); OF\n• Behandelingsnaïeve onderzoeksdeelnemers voor wie, naar het oordeel van de onderzoeker, chirurgie of radiotherapie niet passend wordt geacht;","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815947,"uuid":"fe1093ac-c899-4401-862c-ec26c05c8348","attributeTranslation":"Parte B: alguno de los siguientes:\n• Enfermedad recidivante o resistente después de al menos una línea de tratamiento (incluida la cirugía, la radioterapia o el tratamiento sistémico). O\n• Participantes sin tratamiento previo para los que, en opinión del investigador, no se considere adecuada la cirugía o la radioterapia.","language":7,"languageDescription":"Spanish"}]},{"id":952408,"number":13,"principalInclusionCriteria":"Part B: A desmoid tumor in which continued progressing disease will not result in immediate significant risk to the subject.","principalInclusionCriteriaTranslations":[{"id":11815951,"uuid":"987d2021-0ac1-44f8-b83a-5878a9d32452","attributeTranslation":"Część B: Guz desmoidalny, w przypadku którego dalsza progresja choroby nie spowoduje bezpośredniego znaczącego zagrożenia dla uczestnika","language":19,"languageDescription":"Polish"},{"id":11815949,"uuid":"987d2021-0ac1-44f8-b83a-5878a9d32452","attributeTranslation":"Parte B: un tumor desmoide en el que la progresión continuada de la enfermedad no conllevará un riesgo inmediato para el participante.","language":7,"languageDescription":"Spanish"},{"id":11815950,"uuid":"987d2021-0ac1-44f8-b83a-5878a9d32452","attributeTranslation":"Deel B: Een desmoïde tumor waarbij de voortschrijdende ziekte niet direct tot een significant risico voor de onderzoeksdeelnemer zal leiden.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952409,"number":14,"principalInclusionCriteria":"Part B: Agrees to provide FFPE archival or fresh tumor tissue","principalInclusionCriteriaTranslations":[{"id":11815953,"uuid":"4e76b29e-a884-4c26-9646-e0cfd8372861","attributeTranslation":"Część B: Zgoda na przekazanie archiwalnej lub świeżej tkanki guza w postaci FFPE","language":19,"languageDescription":"Polish"},{"id":11815952,"uuid":"4e76b29e-a884-4c26-9646-e0cfd8372861","attributeTranslation":"Deel B: Gaat akkoord met het verstrekken van FFPE-archief- of vers tumorweefsel","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815954,"uuid":"4e76b29e-a884-4c26-9646-e0cfd8372861","attributeTranslation":"Parte B: acepta proporcionar tejido tumoral FFIP en fresco o de archivo","language":7,"languageDescription":"Spanish"}]},{"id":952410,"number":15,"principalInclusionCriteria":"Part B: Must be able to swallow whole capsules with no GI condition affecting absorption (not including history of colectomy or proctocolectomy); nasogastric or G-tube administration is not allowed","principalInclusionCriteriaTranslations":[{"id":11815956,"uuid":"17cd854e-9040-490c-baef-6b5669e78a90","attributeTranslation":"Część B: Uczestnik musi być w stanie połykać całe kapsułki, bez jakiegokolwiek stanu patologicznego przewodu pokarmowego wpływającego na wchłanianie (co nie obejmuje kolektomii ani proktokolektomii w wywiadzie); niedopuszczalne jest podawanie przez zgłębnik nosowo-żołądkowy ani gastrostomijny.","language":19,"languageDescription":"Polish"},{"id":11815955,"uuid":"17cd854e-9040-490c-baef-6b5669e78a90","attributeTranslation":"Parte B: debe ser capaz de tragar cápsulas enteras sin enfermedad GI que afecte a la absorción (sin incluir los antecedentes de colectomía ni de proctocolectomía); no está permitida la administración mediante sonda nasogástrica o de gastrostomía.","language":7,"languageDescription":"Spanish"},{"id":11815957,"uuid":"17cd854e-9040-490c-baef-6b5669e78a90","attributeTranslation":"Deel B: Moet in staat zijn om hele capsules door te slikken, zonder dat er sprake is van maag-darmproblemen die de absorptie beïnvloeden (met uitzondering van een voorgeschiedenis van colectomie of proctocolectomie); toediening via de neus of maagsonde is niet toegestaan.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952411,"number":16,"principalInclusionCriteria":"OLE: One of the following: a. Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR b. Participating in Part B and were noted to have radiographic progressive disease by BICR, OR c. Are on study treatment (placebo or varegacestat) after completion of Part B","principalInclusionCriteriaTranslations":[{"id":11815959,"uuid":"0756353b-85d5-4edd-8a37-2daf1488ffd5","attributeTranslation":"OLE: Een van de volgende:\na. Nam deel aan Deel A (inclusief MRI in week 16) en zat nog steeds in het onderzoek op het moment dat de dosisselectie voor Deel B/OLE werd gemaakt, OF\nb. Nam deel aan Deel B en had radiografisch progressieve ziekte vastgesteld door BICR, OF\nc. Ontvangt onderzoeksbehandeling (placebo of varegacestat) na afronding van Deel B","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815958,"uuid":"0756353b-85d5-4edd-8a37-2daf1488ffd5","attributeTranslation":"EA: alguno de los siguientes:\na. Ha participado en la parte A (incluida la RM en la semana 16) y seguía en el estudio en el momento en que se realizó la selección de la dosis de la parte B o la EA. O\nb. Participa en la parte B y en la RCIE se observó progresión radiográfica del cáncer. O\nc. Está en tratamiento del estudio (placebo o varegacestat)  después de la finalización de la parte B.","language":7,"languageDescription":"Spanish"},{"id":11815960,"uuid":"0756353b-85d5-4edd-8a37-2daf1488ffd5","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Spełnienie jednego z poniższych warunków:\na. Udział w części A (w tym badanie RM w tygodniu 16) i kontynuacja udziału w badaniu w momencie wyboru dawki w części B/OLE; LUB\nb. Udział w części B i stwierdzenie radiologicznej progresji choroby przez zaślepiony niezależny centralny ośrodek diagnostyczny (ang. Blinded Independent Central Review, BICR); LUB\nc. Przyjmowanie leczenia stosowanego w ramach badania (placebo lub waregacestatu) po zakończeniu Części B","language":19,"languageDescription":"Polish"}]},{"id":952412,"number":17,"principalInclusionCriteria":"OLE: Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed","principalInclusionCriteriaTranslations":[{"id":11815962,"uuid":"b396a2ea-08bd-4da9-b400-5162b0b02e70","attributeTranslation":"EA: debe ser capaz de tragar cápsulas enteras sin enfermedad GI que afecte a la absorción; no está permitida la administración mediante sonda nasogástrica o de gastrostomía","language":7,"languageDescription":"Spanish"},{"id":11815961,"uuid":"b396a2ea-08bd-4da9-b400-5162b0b02e70","attributeTranslation":"OLE: Moet in staat zijn om hele capsules door te slikken, zonder dat er sprake is van maag-darmproblemen die de absorptie beïnvloeden; toediening via de neus of maagsonde is niet toegestaan.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815963,"uuid":"b396a2ea-08bd-4da9-b400-5162b0b02e70","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Uczestnik musi być w stanie połykać całe kapsułki, bez jakiegokolwiek stanu patologicznego przewodu pokarmowego wpływającego na wchłanianie; niedopuszczalne jest podawanie przez zgłębnik nosowo-żołądkowy ani gastrostomijny.","language":19,"languageDescription":"Polish"}]},{"id":952413,"number":18,"principalInclusionCriteria":"OLE: Subject and/or legally authorized representative (i.e. parent/guardian) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.","principalInclusionCriteriaTranslations":[{"id":11815964,"uuid":"49a48e90-2b53-403b-be34-ddeea28725de","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Uczestnik i/lub przedstawiciel ustawowy (tj.\nrodzic/opiekun) musi być w stanie wyrazić pisemną świadomą zgodę, co obejmuje przestrzeganie wymogów i ograniczeń wymienionych w formularzu świadomej zgody","language":19,"languageDescription":"Polish"},{"id":11815965,"uuid":"49a48e90-2b53-403b-be34-ddeea28725de","attributeTranslation":"OLE: Onderzoeksdeelnemer en/of wettelijk gemachtigde vertegenwoordiger (d.w.z.\nouder/voogd) moet in staat zijn om ondertekende geïnformeerde toestemming te geven en moet zich houden aan de vereisten en beperkingen die in het informatie- en toestemmingsformulier staan vermeld.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815966,"uuid":"49a48e90-2b53-403b-be34-ddeea28725de","attributeTranslation":"EA: el participante o el representante legal (es decir,\nprogenitor o tutor legal) debe ser capaz de dar su consentimiento informado firmado, lo que incluye el cumplimiento de los requisitos y restricciones enumerados en el FCI.","language":7,"languageDescription":"Spanish"}]},{"id":952414,"number":19,"principalInclusionCriteria":"OLE: Minor subjects must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).","principalInclusionCriteriaTranslations":[{"id":11815968,"uuid":"19674119-2c86-457b-860b-c9fe4ee5b696","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Nieletni uczestnicy muszą być w stanie wyrazić zgodę na piśmie w zakresie właściwym dla danego wieku (zgodnie z lokalnymi wymogami regulacyjnymi)","language":19,"languageDescription":"Polish"},{"id":11815967,"uuid":"19674119-2c86-457b-860b-c9fe4ee5b696","attributeTranslation":"OLE: Minderjarige onderzoeksdeelnemers moeten in staat zijn om schriftelijke instemming te geven, afhankelijk van de geldende leeftijd (conform de lokale regelgeving).","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815969,"uuid":"19674119-2c86-457b-860b-c9fe4ee5b696","attributeTranslation":"EA: los participantes menores deben ser capaces de otorgar el asentimiento por escrito adecuado para su edad (de acuerdo con los requisitos normativos locales).","language":7,"languageDescription":"Spanish"}]},{"id":952415,"number":2,"principalInclusionCriteria":"Part A: Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent).","principalInclusionCriteriaTranslations":[{"id":11815971,"uuid":"988f67c3-238b-4986-905a-97747bdfa32c","attributeTranslation":"Część A: Histologiczne potwierdzenie guza desmoidalnego (agresywna włókniakowatość) przez miejscowego patomorfologa (przed udzieleniem świadomej zgody).","language":19,"languageDescription":"Polish"},{"id":11815972,"uuid":"988f67c3-238b-4986-905a-97747bdfa32c","attributeTranslation":"Parte A: tumor desmoide confirmado histológicamente (fibromatosis agresiva) por un anatomopatólogo local (antes del consentimiento informado).","language":7,"languageDescription":"Spanish"},{"id":11815970,"uuid":"988f67c3-238b-4986-905a-97747bdfa32c","attributeTranslation":"Deel A: Histologisch bevestigde desmoïde tumor (agressieve fibromatose) door een plaatselijke patholoog (voorafgaand aan geïnformeerde toestemming).","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952416,"number":20,"principalInclusionCriteria":"Other protocol defined inclusion criteria could apply","principalInclusionCriteriaTranslations":[{"id":11815974,"uuid":"2efd88c9-c2e0-4675-8493-eea0e37bc9ab","attributeTranslation":"Podrían aplicarse otros criterios de inclusión definidos en el protocolo","language":7,"languageDescription":"Spanish"},{"id":11815975,"uuid":"2efd88c9-c2e0-4675-8493-eea0e37bc9ab","attributeTranslation":"Andere in het protocol omschreven inclusiecriteria kunnen van toepassing zijn","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815973,"uuid":"2efd88c9-c2e0-4675-8493-eea0e37bc9ab","attributeTranslation":"Zastosowanie mogą mieć inne kryteria włączenia zdefiniowane w protokole.","language":19,"languageDescription":"Polish"}]},{"id":952417,"number":3,"principalInclusionCriteria":"Part A: Disease progression, assessed by the investigator, defined as having at least one of the following: a) Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI b) Having desmoid tumor-related pain that is not adequately controlled with non-opioid medication","principalInclusionCriteriaTranslations":[{"id":11815978,"uuid":"a74e92fd-b120-4914-bd87-3bf93a01b9c7","attributeTranslation":"Deel A: Ziekteprogressie, beoordeeld door de onderzoeker, gedefinieerd als de aanwezigheid van ten minste een van de volgende:\na) unidimensionale groei van desmoïde tumor(en) met ≥ 10%, gebruikmakend van de som van de grootste diameters van de doellaesie(s), binnen 18 maanden na de MRI bij de keuring\nb) pijn die verband houdt met een desmoïde tumor en die niet adequaat onder controle is met niet-opioïde medicatie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815977,"uuid":"a74e92fd-b120-4914-bd87-3bf93a01b9c7","attributeTranslation":"Część A: Progresja choroby w ocenie badacza, zdefiniowana jako spełnienie co najmniej jednego z następujących warunków:\na) jednowymiarowy wzrost guza desmoidalnego (guzów desmoidalnych) o ≥10%, oceniony na podstawie największych wymiarów zmiany docelowej (zmian docelowych) w ciągu 18 miesięcy przed przesiewowym badaniem RM\nb) ból związany z guzem desmoidalnym, który nie jest odpowiednio kontrolowany za pomocą leków nieopioidowych","language":19,"languageDescription":"Polish"},{"id":11815976,"uuid":"a74e92fd-b120-4914-bd87-3bf93a01b9c7","attributeTranslation":"Parte A: progresión de la enfermedad, evaluada por el investigador, definida como presentar al menos uno de los siguientes:\na) Crecimiento unidimensional del tumor o tumores desmoides en ≥10 %, usando la suma de los diámetros más grandes de las lesiones objetivo, en los 18 meses anteriores a la RM de selección.\nb) Presentar dolor relacionado con el tumor desmoide que no esté controlado de forma suficiente con medicamentos no opioides.","language":7,"languageDescription":"Spanish"}]},{"id":952418,"number":4,"principalInclusionCriteria":"Part A: At least 1 measurable lesion amenable to volume measurements by MRI at screening","principalInclusionCriteriaTranslations":[{"id":11815979,"uuid":"c44e92c1-78c2-4856-bcca-24dbc55215b8","attributeTranslation":"Część A: Obecność co najmniej 1 zmiany nadającej się do pomiaru objętości stwierdzonej w przesiewowym badaniu RM","language":19,"languageDescription":"Polish"},{"id":11815981,"uuid":"c44e92c1-78c2-4856-bcca-24dbc55215b8","attributeTranslation":"Parte A: al menos 1 lesión medible susceptible de mediciones de volumen por RM en la selección.","language":7,"languageDescription":"Spanish"},{"id":11815980,"uuid":"c44e92c1-78c2-4856-bcca-24dbc55215b8","attributeTranslation":"Deel A: Ten minste 1 meetbare laesie die geschikt is voor volumemetingen door MRI bij de keuring","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952419,"number":5,"principalInclusionCriteria":"Part A: One of the following: • Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate; OR • Recurrent/refractory disease following at least one line of therapy(including surgery, radiation, or systemic therapy).","principalInclusionCriteriaTranslations":[{"id":11815984,"uuid":"0baa3ffd-aeaa-4c40-9a4f-17e21750263c","attributeTranslation":"Część A: Spełnienie jednego z poniższych warunków:\n• Nieleczeni wcześniej uczestnicy, w przypadku których w opinii badacza, badany produkt (BP) uważany jest za właściwy; LUB\n• Choroba nawrotowa/oporna na leczenie po zastosowaniu co najmniej jednego rzutu leczenia (w tym zabiegu chirurgicznego, radioterapii lub leczenia ogólnoustrojowego).","language":19,"languageDescription":"Polish"},{"id":11815982,"uuid":"0baa3ffd-aeaa-4c40-9a4f-17e21750263c","attributeTranslation":"Parte A: alguno de los siguientes:\n• Participantes sin tratamiento previo para los que, en opinión del investigador, se considere adecuado el PEI. O\n• Enfermedad recidivante o resistente después de al menos una línea de tratamiento (incluida la cirugía, la radioterapia o el tratamiento sistémico).","language":7,"languageDescription":"Spanish"},{"id":11815983,"uuid":"0baa3ffd-aeaa-4c40-9a4f-17e21750263c","attributeTranslation":"Deel A: Een van de volgende:\n• Behandelingsnaïeve onderzoeksdeelnemers voor wie, naar het oordeel van de onderzoeker, het onderzoeksmiddel passend wordt geacht; OF\n• Terugkerende/refractaire ziekte na ten minste één therapielijn (waaronder chirurgie, bestraling of systemische therapie).","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952420,"number":6,"principalInclusionCriteria":"Part A: A desmoid tumor in which continued progressing disease will not result in immediate significant risk to the subject","principalInclusionCriteriaTranslations":[{"id":11815987,"uuid":"835bd08e-354f-455c-ac99-08c478bd4685","attributeTranslation":"Część A: Guz desmoidalny, w przypadku którego dalsza progresja choroby nie spowoduje bezpośredniego znaczącego zagrożenia dla uczestnika","language":19,"languageDescription":"Polish"},{"id":11815985,"uuid":"835bd08e-354f-455c-ac99-08c478bd4685","attributeTranslation":"Parte A: un tumor desmoide en el que la progresión continuada de la enfermedad no conllevará un riesgo inmediato para el participante.","language":7,"languageDescription":"Spanish"},{"id":11815986,"uuid":"835bd08e-354f-455c-ac99-08c478bd4685","attributeTranslation":"Deel A: Een desmoïde tumor waarbij de voortschrijdende ziekte niet direct tot een significant risico voor de onderzoeksdeelnemer zal leiden","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952421,"number":7,"principalInclusionCriteria":"Part A: Agrees to provide formalin-fixed paraffin embedded (FFPE) archival or fresh tumor tissue.","principalInclusionCriteriaTranslations":[{"id":11815989,"uuid":"86e1539a-80b2-4c8c-b06a-299ad12a0ec0","attributeTranslation":"Parte A: acepta proporcionar tejido tumoral fijado en formol e incluido en parafina (FFIP) de archivo o en fresco.","language":7,"languageDescription":"Spanish"},{"id":11815988,"uuid":"86e1539a-80b2-4c8c-b06a-299ad12a0ec0","attributeTranslation":"Część A: Zgoda na przekazanie archiwalnej lub świeżej tkanki guza utrwalonej w formalinie i zatopionej w parafinie (ang. Formalin-Fixed Paraffin Embedded, FFPE)","language":19,"languageDescription":"Polish"},{"id":11815990,"uuid":"86e1539a-80b2-4c8c-b06a-299ad12a0ec0","attributeTranslation":"Deel A: Gaat akkoord met het leveren van formaline-gefixeerd, in paraffine ingebed (FFPE) archief- of vers tumorweefsel.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":952422,"number":8,"principalInclusionCriteria":"Part A: Must be able to swallow whole capsules with no GI condition affecting absorption (not including history of colectomy); nasogastric or G-tube administration is not allowed.","principalInclusionCriteriaTranslations":[{"id":11815993,"uuid":"da9fedf4-4e09-468a-83ed-cc000290748a","attributeTranslation":"Deel A: Moet in staat zijn om hele capsules door te slikken, zonder dat er sprake is van gastro-intestinale problemen die de absorptie beïnvloeden (met uitzondering van een voorgeschiedenis van colectomie); toediening via de neus of maagsonde is niet toegestaan.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815991,"uuid":"da9fedf4-4e09-468a-83ed-cc000290748a","attributeTranslation":"Część A: Uczestnik musi być w stanie połykać całe kapsułki, bez jakiegokolwiek stanu patologicznego przewodu pokarmowego wpływającego na wchłanianie (co nie obejmuje kolektomii w wywiadzie); niedopuszczalne jest podawanie przez zgłębnik nosowo-żołądkowy ani gastrostomijny.","language":19,"languageDescription":"Polish"},{"id":11815992,"uuid":"da9fedf4-4e09-468a-83ed-cc000290748a","attributeTranslation":"Parte A: debe ser capaz de tragar cápsulas enteras sin enfermedad GI que afecte a la absorción (sin incluir los antecedentes de colectomía); no está permitida la administración mediante sonda nasogástrica o de gastrostomía.","language":7,"languageDescription":"Spanish"}]},{"id":952423,"number":9,"principalInclusionCriteria":"Part B: 1. ≥12 years of age (inclusive) in countries which allow participation of adolescents and ≥ 40 kg at the time of signing the ICF.","principalInclusionCriteriaTranslations":[{"id":11815995,"uuid":"54b9a614-a3cd-4140-8e7a-c2ac87c6cf9c","attributeTranslation":"Część B: 1. wiek co najmniej 12 lat (włącznie) w krajach, które pozwalają na udział osób małoletnich i masa ciała co najmniej 40 kg w momencie podpisania formularza świadomej zgody.","language":19,"languageDescription":"Polish"},{"id":11815996,"uuid":"54b9a614-a3cd-4140-8e7a-c2ac87c6cf9c","attributeTranslation":"Deel B: 1. ≥ 12 jaar (inclusief) in landen die deelname van adolescenten toestaan en ≥ 40 kg wegen op het moment van ondertekening van het informatie- en toestemmingsformulier.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815994,"uuid":"54b9a614-a3cd-4140-8e7a-c2ac87c6cf9c","attributeTranslation":"Parte B: 1. ≥12 años de edad (inclusive) en países que permitan la participación de adolescentes y ≥40 kg en el momento de la firma del FCI.","language":7,"languageDescription":"Spanish"}]}],"principalExclusionCriteria":[{"id":1626636,"number":1,"principalExclusionCriteria":"Part A: Diagnosed with a malignancy in the past 2 years, unless for protocol defined allowed malignancies","principalExclusionCriteriaTranslations":[{"id":11815855,"uuid":"23e5093f-a8af-4fc7-ad28-2b181bb1ce7e","attributeTranslation":"Część A: Rozpoznanie nowotworu złośliwego w ciągu ostatnich 2 lat, z wyjątkiem zdefiniowanych w protokole nowotworów złośliwych","language":19,"languageDescription":"Polish"},{"id":11815853,"uuid":"23e5093f-a8af-4fc7-ad28-2b181bb1ce7e","attributeTranslation":"Parte A: diagnosticado de una neoplasia maligna en los últimos 2 años, excepto las neoplasias malignas permitidas definidas por el protocolo.","language":7,"languageDescription":"Spanish"},{"id":11815854,"uuid":"23e5093f-a8af-4fc7-ad28-2b181bb1ce7e","attributeTranslation":"Deel A: Heeft een diagnose van een maligniteit in de afgelopen 2 jaar, tenzij voor door het protocol gedefinieerde toegestane maligniteiten","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626637,"number":10,"principalExclusionCriteria":"Part A: ECG Exclusions: a. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec; b. QRS duration > 110 ms; c. PR interval > 240 ms; d. Marked ST-T wave abnormalities which would make it difficult to measure the QT interval","principalExclusionCriteriaTranslations":[{"id":11815858,"uuid":"bb99703d-cdac-42b8-9bb1-585110375e57","attributeTranslation":"Deel A: Ecg-uitsluitingen: a. Gemiddeld QT-interval gecorrigeerd voor hartslag met behulp van de formule van Fridericia (QTcF) ≥ 450 msec; b. QRS-duur > 110 ms; c. PR-interval > 240 ms; d. Duidelijke ST-T-golfafwijkingen die het moeilijk maken om het QT-interval te meten","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815856,"uuid":"bb99703d-cdac-42b8-9bb1-585110375e57","attributeTranslation":"Część A: Wykluczające obserwacje EKG: a Średni odstęp QT skorygowany względem częstości akcji serca przy użyciu wzoru Fridericia (QTcF) ≥450 ms; b. czas trwania QRS >110 ms; c. Odstęp PR >240 ms; d. Znaczące nieprawidłowości załamków ST-T, które utrudniałyby zmierzenie odstępu QT","language":19,"languageDescription":"Polish"},{"id":11815857,"uuid":"bb99703d-cdac-42b8-9bb1-585110375e57","attributeTranslation":"Parte A: exclusiones por ECG: a. Intervalo QT corregido para la frecuencia cardíaca mediante la fórmula de Fridericia (QTcF) ≥450 ms; b. Duración QRS >110 ms; c. Intervalo PR >240 ms; d. Anomalías marcadas de la onda ST-T que podrían dificultar la medición del intervalo QT.","language":7,"languageDescription":"Spanish"}]},{"id":1626638,"number":11,"principalExclusionCriteria":"Part B: Diagnosed with a malignancy in the past 2 years, unless for protocol defined allowed malignancies","principalExclusionCriteriaTranslations":[{"id":11815860,"uuid":"17cd8cf5-eb25-4fab-8ed3-b2c28f70271d","attributeTranslation":"Część B: Rozpoznanie nowotworu złośliwego w ciągu ostatnich 2 lat, z wyjątkiem zdefiniowanych w protokole nowotworów złośliwych","language":19,"languageDescription":"Polish"},{"id":11815861,"uuid":"17cd8cf5-eb25-4fab-8ed3-b2c28f70271d","attributeTranslation":"Deel B: Heeft een diagnose van een maligniteit in de afgelopen 2 jaar, tenzij voor door het protocol gedefinieerde toegestane maligniteiten","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815859,"uuid":"17cd8cf5-eb25-4fab-8ed3-b2c28f70271d","attributeTranslation":"Parte B: diagnosticado de una neoplasia maligna en los últimos 2 años, excepto las neoplasias malignas permitidas definidas por el protocolo.","language":7,"languageDescription":"Spanish"}]},{"id":1626639,"number":12,"principalExclusionCriteria":"Part B: Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease","principalExclusionCriteriaTranslations":[{"id":11815863,"uuid":"c555339a-5647-4832-99e0-65e3ecb6f0ad","attributeTranslation":"Część B: Występująca obecnie lub niedawno (w ciągu dwóch miesięcy przed podaniem BP) choroba lub zaburzenie przewodu pokarmowego, które zwiększa ryzyko biegunki, takie jak nieswoiste zapalenie jelit czy choroba Leśniowskiego-Crohna","language":19,"languageDescription":"Polish"},{"id":11815862,"uuid":"c555339a-5647-4832-99e0-65e3ecb6f0ad","attributeTranslation":"Deel B: Huidige of recente (binnen 2 maanden na toediening van het onderzoeksmiddel) maag-darmziekte of aandoeningen die het risico op diarree vergroten, zoals inflammatoire darmziekte en de ziekte van Crohn","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815864,"uuid":"c555339a-5647-4832-99e0-65e3ecb6f0ad","attributeTranslation":"Parte B: enfermedad o trastornos GI actuales o recientes (en los 2 meses previos a la administración del PEI) que aumentan el riesgo de diarrea, tales como la enfermedad inflamatoria intestinal y la enfermedad de Crohn.","language":7,"languageDescription":"Spanish"}]},{"id":1626640,"number":13,"principalExclusionCriteria":"Part B: Evidence of uncontrolled, active infection, requiring systemic antibacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP","principalExclusionCriteriaTranslations":[{"id":11815866,"uuid":"c13221ed-28b5-4faa-9ded-2ab6bb06b0b4","attributeTranslation":"Deel A: Abnormale orgaan- en beenmergfunctie bij keuring, gedefinieerd als: a. Neutrofielen < 1500/mm3; b. Bloedplaatjesaantal < 100.000/mm3; c. Hemoglobine < 9 g/dl; d. Elektrolyten (kalium, calcium, magnesium en fosfor, met gebruikmaking van de gecorrigeerde waarde indien er sprake is van een laag serumalbuminegehalte) buiten de normale limieten van het lokale laboratorium; e. Totaal\nbilirubine > 1,5 x ULN (behalve bekend syndroom van Gilbert > 3 x ULN); f. Aspartaataminotransferase (ASAT) en alanine-aminotransferase (ALAT) > 2,5 x ULN; g. Serum- of plasmacreatinine > ULN en creatinineklaring (CrCl) < 60 ml/min; h. Ongecontroleerde triglyceridetoename ≥ graad 2 volgens CTCAE v5.0 (> 300 mg/dl of > 3,42 mmol/l)","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815867,"uuid":"c13221ed-28b5-4faa-9ded-2ab6bb06b0b4","attributeTranslation":"Parte B: indicios de infección activa no controlada que requiere tratamiento sistémico antibacteriano, antivírico o antifúngico ≤7 días antes de la administración del PEI.","language":7,"languageDescription":"Spanish"},{"id":11815865,"uuid":"c13221ed-28b5-4faa-9ded-2ab6bb06b0b4","attributeTranslation":"Część B: dowody na występowanie niekontrolowanego, czynnego zakażenia, wymagającego ogólnoustrojowego leczenia przeciwbakteryjnego, przeciwwirusowego lub przeciwgrzybiczego na ≤7 dni przed podaniem BP","language":19,"languageDescription":"Polish"}]},{"id":1626641,"number":14,"principalExclusionCriteria":"Part B: Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has NYHA Class III or IV heart failure, symptomatic ventricular arrhythmias, sustained ventricular tachycardia, TdP, the long QT syndrome, pacemaker dependence, or electrocardiographic evidence of acute ischemia","principalExclusionCriteriaTranslations":[{"id":11815868,"uuid":"2ccd3280-ad01-40e1-8911-0fcfc5ba97fe","attributeTranslation":"Deel B: Bewijs van ongecontroleerde, actieve infectie, waarvoor systemische antibacteriële, antivirale of antischimmeltherapie nodig is ≤ 7 dagen vóór toediening van het onderzoeksmiddel","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815869,"uuid":"2ccd3280-ad01-40e1-8911-0fcfc5ba97fe","attributeTranslation":"Parte B: infarto de miocardio en los 6 meses anteriores a la inclusión, mayor que la angina de pecho de clase 1, o tiene insuficiencia cardíaca de clase III o IV según la Asociación Cardiológica de Nueva York (New York Heart Association, NYHA), arritmias ventriculares sintomáticas, taquicardia ventricular sostenida, taquicardia helicoidal, síndrome de QT largo, dependencia de marcapasos o signos electrocardiográficos de isquemia aguda.","language":7,"languageDescription":"Spanish"},{"id":11815870,"uuid":"2ccd3280-ad01-40e1-8911-0fcfc5ba97fe","attributeTranslation":"Część B: zawał mięśnia sercowego w ciągu sześciu miesięcy poprzedzających włączenie do badania, dusznica bolesna klasy większej niż 1, niewydolność serca klasy III lub IV w skali Nowojorskiego Towarzystwa Kardiologicznego (ang. New York Heart Association, NYHA), objawowe zaburzenia rytmu serca, utrzymujący się częstoskurcz komorowy, torsade de pointes, zespół wydłużonego odcinka QT, zależność od rozrusznika serca lub obserwacje z EKG elektrokardiograficzne wskazujące na ostre niedokrwienie","language":19,"languageDescription":"Polish"}]},{"id":1626642,"number":15,"principalExclusionCriteria":"Part B: History of additional risk factors for TdP","principalExclusionCriteriaTranslations":[{"id":11815873,"uuid":"bd03d081-fdaa-45f6-bf10-3dc912fe2973","attributeTranslation":"Deel B: Myocardinfarct binnen 6 maanden voorafgaand aan de insluiting, erger dan angina pectoris van klasse 1, of hartfalen van NYHA-klasse III of IV, symptomatische ventriculaire aritmieën, aanhoudende ventriculaire tachycardie, TdP, het lange QT-syndroom, pacemakerafhankelijkheid of \nelektrocardiografisch bewijs van acute ischemie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815872,"uuid":"bd03d081-fdaa-45f6-bf10-3dc912fe2973","attributeTranslation":"Parte B: antecedentes de factores de riesgo adicionales para la taquicardia helicoidal.","language":7,"languageDescription":"Spanish"},{"id":11815871,"uuid":"bd03d081-fdaa-45f6-bf10-3dc912fe2973","attributeTranslation":"Część B: Obecne w wywiadzie dodatkowe czynniki ryzyka wystąpienia torsade de pointes","language":19,"languageDescription":"Polish"}]},{"id":1626643,"number":16,"principalExclusionCriteria":"Part B: Unstable or severe uncontrolled medical condition or any important medical illness or abnormal laboratory finding","principalExclusionCriteriaTranslations":[{"id":11815876,"uuid":"455b192b-b718-490b-8095-b20b77b0bb6f","attributeTranslation":"Część B: Niestabilny lub ciężki niekontrolowany stan internistyczny lub jakiekolwiek istotna choroba internistyczna lub nieprawidłowy wynik badań laboratoryjnych","language":19,"languageDescription":"Polish"},{"id":11815874,"uuid":"455b192b-b718-490b-8095-b20b77b0bb6f","attributeTranslation":"Parte B: enfermedades inestables o graves no controladas, o cualquier afección importante o hallazgo analítico anómalo.","language":7,"languageDescription":"Spanish"},{"id":11815875,"uuid":"455b192b-b718-490b-8095-b20b77b0bb6f","attributeTranslation":"Deel B: Onstabiele of ernstige ongecontroleerde medische aandoening of een belangrijke medische ziekte of abnormale laboratoriumbevindingen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626644,"number":17,"principalExclusionCriteria":"Part B: Pregnant or breastfeeding or expecting to conceive children during the study","principalExclusionCriteriaTranslations":[{"id":11815877,"uuid":"ffdec431-972c-4161-8909-86dab57d0f93","attributeTranslation":"Część B: Ciąża, karmienie piersią lub oczekiwane poczęcie dziecka w trakcie udziału w badaniu","language":19,"languageDescription":"Polish"},{"id":11815878,"uuid":"ffdec431-972c-4161-8909-86dab57d0f93","attributeTranslation":"Deel B: Is zwanger of geeft borstvoeding of is van plan kinderen te verwekken tijdens het onderzoek","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815879,"uuid":"ffdec431-972c-4161-8909-86dab57d0f93","attributeTranslation":"Parte B: estar embarazada, en periodo de lactancia o planificar un embarazo durante el estudio","language":7,"languageDescription":"Spanish"}]},{"id":1626645,"number":18,"principalExclusionCriteria":"Part B: ECOG performance status ≥2","principalExclusionCriteriaTranslations":[{"id":11815882,"uuid":"6e6d5709-08f2-4c78-8076-3b42f7d4b682","attributeTranslation":"Część B: Stan sprawności w skali Wschodniej Grupy Współpracy Onkologicznej (ang. Eastern Cooperative Oncology Group, ECOG) ≥2","language":19,"languageDescription":"Polish"},{"id":11815880,"uuid":"6e6d5709-08f2-4c78-8076-3b42f7d4b682","attributeTranslation":"Deel B: ECOG-prestatiestatus ≥ 2","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815881,"uuid":"6e6d5709-08f2-4c78-8076-3b42f7d4b682","attributeTranslation":"Parte B: estado funcional ≤2 según el Grupo Oncológico Cooperativo de la Costa Este de los EE. UU. (Eastern Cooperative Oncology Group, ECOG).","language":7,"languageDescription":"Spanish"}]},{"id":1626646,"number":19,"principalExclusionCriteria":"Part B: Abnormal organ and marrow function at Screening defined as: a.Neutrophils <1500/mm3; b. Platelet count <100,000/mm3; c.Hemoglobin <9 g/dL; d. Electrolytes (potassium, calcium, magnesium,and phosphorus, using corrected value if low serum albumin level is present) outside the normal limits of the local laboratory; e. Total bilirubin >1.5x ULN (except known Gilbert's syndrome >3x ULN); f. AST and ALT >2.5x ULN; g. Serum or plasma creatinine > ULN and CrCl <60 mL/min (calculation of CrCl will be based on acceptable institution standard); h.Uncontrolled triglyceride ≥Grade 2 elevations per CTCAE v5.0 (>300 mg/dL or >3.42 mmol/L); i.Any other laboratory abnormality ≥Grade 3","principalExclusionCriteriaTranslations":[{"id":11815883,"uuid":"1ecc60af-860b-4ba6-bc6a-201eace623b7","attributeTranslation":"Parte B: funcionamiento anómalo de la médula ósea y los órganos en la selección definida como: a. Neutrófilos <1500/mm3; b. Cifra de trombocitos <100 000/mm3; c. Hemoglobina <9 g/dl; d. Electrólitos (potasio, calcio, magnesio y fósforo, mediante el valor corregido si existe una concentración baja de seroalbúmina) fuera de los límites normales del laboratorio local; e. Bilirrubina total >1,5 × LSN \n(excepto con síndrome de Gilbert conocido >3 × LSN); f. AST y ALT >2,5 × LSN; g. Creatinina sérica o plasmática >LSN y ACr <60 ml/min (el cálculo del ACr se basará en el estándar aceptable del centro); h. Elevaciones de triglicéridos de grado ≥2 según los CTCAE v5.0 (>300 mg/dl o >3,42 mmol/l); i. Cualquier otra anomalía analítica de grado ≥3.","language":7,"languageDescription":"Spanish"},{"id":11815884,"uuid":"1ecc60af-860b-4ba6-bc6a-201eace623b7","attributeTranslation":"Deel B: Abnormale orgaan- en beenmergfunctie bij keuring gedefinieerd als: a. Neutrofielen < 1500/mm3; b. Bloedplaatjesaantal < 100.000/mm3; c. Hemoglobine < 9 g/dl; d. Elektrolyten (kalium, calcium, magnesium en fosfor, met gebruikmaking van de gecorrigeerde waarde indien er sprake is van een laag serumalbuminegehalte) buiten de normale limieten van het lokale laboratorium; e. Totaal\nbilirubine >1,5 x ULN (behalve bekend syndroom van Gilbert >3 x ULN); f. ASAT en ALAT > 2,5 x ULN; g. Serum- of plasmacreatinine > ULN en CrCl < 60 ml/min (de CrCl zal worden berekend op basis van acceptabele instellingsnormen); h. Ongecontroleerde triglyceridetoename ≥ graad 2 volgens CTCAE v5.0 (> 300 mg/dl or > 3,42 mmol/l); i. Een andere afwijking van de laboratoriumwaarden ≥ graad 3","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815885,"uuid":"1ecc60af-860b-4ba6-bc6a-201eace623b7","attributeTranslation":"Część B: Nieprawidłowa czynność narządów i szpiku kostnego podczas badania przesiewowego zdefiniowana jako: a. Liczba neutrofili <1500/mm3; b. Liczba płytek krwi <100 000/mm3; c. Stężenie hemoglobiny <9 g/dl; d. Stężenie elektrolitów (potasu, wapnia, magnezu i fosforu przy użyciu skorygowanej wartości, jeśli stężenie albumin w surowicy jest małe) wykraczające poza zakres normy przyjęty przez miejscowe laboratorium; e. Stężenie \nbilirubiny całkowitej >1,5 x GGN (w przypadku rozpoznanego zespołu Gilberta >3 x GGN); f. Aktywność AST i ALT > 2,5 x GGN; g. stężenie kreatyniny w surowicy lub w osoczu >GGN i CrCl <60 ml/min; (obliczenie CrCl będzie oparte na standardzie przyjętym przez instytucję); h. Nieopanowany wzrost poziomu trójglicerydów stopnia ≥2 wg kryteriów CTCAE w wersji 5.0 (>300 mg/dl lub >3,42 mmol/l); i. Wszelkie inne nieprawidłowe wyniki badań laboratoryjnych stopnia ≥3","language":19,"languageDescription":"Polish"}]},{"id":1626647,"number":2,"principalExclusionCriteria":"Part A: Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease","principalExclusionCriteriaTranslations":[{"id":11815886,"uuid":"40cc8cbf-614b-407d-b578-5389cef52e89","attributeTranslation":"Część A: Występująca obecnie lub niedawno (w ciągu dwóch miesięcy przed podaniem BP) choroba lub zaburzenie przewodu pokarmowego, które zwiększa ryzyko biegunki, takie jak nieswoiste zapalenie jelit czy choroba Leśniowskiego-Crohna","language":19,"languageDescription":"Polish"},{"id":11815888,"uuid":"40cc8cbf-614b-407d-b578-5389cef52e89","attributeTranslation":"Deel A: Huidige of recente (binnen 2 maanden na toediening van het onderzoeksmiddel) maag-darmziekte of aandoeningen die het risico op diarree vergroten, zoals inflammatoire darmziekte en de ziekte van Crohn","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815887,"uuid":"40cc8cbf-614b-407d-b578-5389cef52e89","attributeTranslation":"Parte A: enfermedad o trastornos GI actuales o recientes (en los 2 meses previos a la administración del PEI) que aumentan el riesgo de diarrea, tales como la enfermedad inflamatoria intestinal y la enfermedad de Crohn.","language":7,"languageDescription":"Spanish"}]},{"id":1626648,"number":20,"principalExclusionCriteria":"Part B: ECG Exclusions: a. Mean QTcF ≥450 msec; b. Second or third degree AV block","principalExclusionCriteriaTranslations":[{"id":11815891,"uuid":"4c351e72-9902-4bd1-94fa-ceb2caf08f8d","attributeTranslation":"Część B: Wykluczające obserwacje EKG: a Średnia wartość QTcF ≥450 ms; b. Blok przedsionkowo-komorowy (p-k) drugiego lub trzeciego stopnia","language":19,"languageDescription":"Polish"},{"id":11815890,"uuid":"4c351e72-9902-4bd1-94fa-ceb2caf08f8d","attributeTranslation":"Parte B: exclusiones por ECG: a. QTcF medio ≥450 ms; b. Bloqueo AV de tercer grado.","language":7,"languageDescription":"Spanish"},{"id":11815889,"uuid":"4c351e72-9902-4bd1-94fa-ceb2caf08f8d","attributeTranslation":"Deel B: Ecg-uitsluitingen: a. Gemiddelde QTcF ≥ 450 msec; b. AV-blok van de tweede of derde graad","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626649,"number":21,"principalExclusionCriteria":"OLE: Unstable or severe uncontrolled medical condition or any important medical illness, abnormal ECG or laboratory finding.","principalExclusionCriteriaTranslations":[{"id":11815893,"uuid":"be9134b0-5864-4c2d-b641-bee3333aeea4","attributeTranslation":"EA: enfermedad inestable o grave no controlada o cualquier afección importante, hallazgos analíticos o ECG anómalos.","language":7,"languageDescription":"Spanish"},{"id":11815892,"uuid":"be9134b0-5864-4c2d-b641-bee3333aeea4","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Niestabilny lub ciężki niekontrolowany stan internistyczny lub jakiekolwiek istotna choroba internistyczna lub nieprawidłowy wynik EKG lub badań laboratoryjnych","language":19,"languageDescription":"Polish"},{"id":11815894,"uuid":"be9134b0-5864-4c2d-b641-bee3333aeea4","attributeTranslation":"OLE: Onstabiele of ernstige ongecontroleerde medische aandoening of een belangrijke medische ziekte, abnormale ecg of abnormale laboratoriumbevindingen.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626650,"number":22,"principalExclusionCriteria":"OLE: Ongoing TEAE from Part A or Part B that requires discontinuation","principalExclusionCriteriaTranslations":[{"id":11815896,"uuid":"8f516131-618b-425d-9151-4699696c433d","attributeTranslation":"EA: AADT en curso desde la parte A o de la parte B que obliga a la suspensión.","language":7,"languageDescription":"Spanish"},{"id":11815895,"uuid":"8f516131-618b-425d-9151-4699696c433d","attributeTranslation":"OLE: Niet opgeloste TEAE van Deel A of Deel B waarvoor stopzetting vereist is","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815897,"uuid":"8f516131-618b-425d-9151-4699696c433d","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Utrzymujące się zdarzenie niepożądane zaistniałe w trakcie leczenia (ang. Treatment Emergent Adverse Events, TEAE) z Części A lub Części B, które wymagają przerwania leczenia","language":19,"languageDescription":"Polish"}]},{"id":1626651,"number":23,"principalExclusionCriteria":"OLE: Breastfeeding or expecting to conceive children within the projected duration of the study","principalExclusionCriteriaTranslations":[{"id":11815899,"uuid":"609ea652-67b2-4cc5-961b-15e42d8d40cd","attributeTranslation":"OLE: Geeft borstvoeding of is van plan binnen de verwachte duur van het onderzoek zwanger te worden","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815898,"uuid":"609ea652-67b2-4cc5-961b-15e42d8d40cd","attributeTranslation":"EA: estar en periodo de lactancia o planificar un embarazo durante el periodo previsto del estudio.","language":7,"languageDescription":"Spanish"},{"id":11815900,"uuid":"609ea652-67b2-4cc5-961b-15e42d8d40cd","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Karmienie piersią lub oczekiwane poczęcia dziecka w przewidywanym czasie trwania badania","language":19,"languageDescription":"Polish"}]},{"id":1626652,"number":24,"principalExclusionCriteria":"OLE: Use of any therapy that is prohibited in Part A or Part B of the study.","principalExclusionCriteriaTranslations":[{"id":11815902,"uuid":"5bfcaa83-72b7-45e2-bf5c-2d0f319bdb6b","attributeTranslation":"EA: uso de cualquier tratamiento prohibido en la parte A o la parte B del estudio.","language":7,"languageDescription":"Spanish"},{"id":11815901,"uuid":"5bfcaa83-72b7-45e2-bf5c-2d0f319bdb6b","attributeTranslation":"OLE: Gebruik van een therapie die verboden is in Deel A of Deel B van het onderzoek.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815903,"uuid":"5bfcaa83-72b7-45e2-bf5c-2d0f319bdb6b","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Stosowanie jakichkolwiek metod leczenia zabronionych w Części A lub Części B badania","language":19,"languageDescription":"Polish"}]},{"id":1626653,"number":25,"principalExclusionCriteria":"OLE: Concurrent enrollment in another clinical study unless it is an observational (non-interventional) clinical study","principalExclusionCriteriaTranslations":[{"id":11815904,"uuid":"c1a2fd4c-669c-49dd-9b2f-07d40dcce956","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Równoczesny udział w innym badaniu klinicznym, chyba że jest to obserwacyjne (nieinterwencyjne) badanie kliniczne","language":19,"languageDescription":"Polish"},{"id":11815905,"uuid":"c1a2fd4c-669c-49dd-9b2f-07d40dcce956","attributeTranslation":"EA: inclusión simultánea en otro estudio clínico, a menos que sea un estudio clínico observacional (no intervencionista).","language":7,"languageDescription":"Spanish"},{"id":11815906,"uuid":"c1a2fd4c-669c-49dd-9b2f-07d40dcce956","attributeTranslation":"OLE: Gelijktijdige insluiting in een ander klinisch onderzoek, tenzij het een observationeel (niet-interventioneel) klinisch onderzoek is","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626654,"number":26,"principalExclusionCriteria":"OLE: Hypersensitivity to AL102 and any of its excipients","principalExclusionCriteriaTranslations":[{"id":11815909,"uuid":"b8f15aab-8b58-48c8-beeb-dff9e8ee5493","attributeTranslation":"OLE: Overgevoeligheid voor AL102 en een van de hulpstoffen","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815908,"uuid":"b8f15aab-8b58-48c8-beeb-dff9e8ee5493","attributeTranslation":"EA: hipersensibilidad al AL102 y a cualquiera de sus excipientes.","language":7,"languageDescription":"Spanish"},{"id":11815907,"uuid":"b8f15aab-8b58-48c8-beeb-dff9e8ee5493","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Nadwrażliwość na AL102 lub którąkolwiek z substancji pomocniczych tego produktu","language":19,"languageDescription":"Polish"}]},{"id":1626655,"number":27,"principalExclusionCriteria":"Other protocol defined exclusion criteria could apply","principalExclusionCriteriaTranslations":[{"id":11815912,"uuid":"9a28354c-06ee-4aa5-a88e-83da5b5ba74f","attributeTranslation":"Podrían aplicarse otros criterios de exclusión definidos en el protocolo.","language":7,"languageDescription":"Spanish"},{"id":11815911,"uuid":"9a28354c-06ee-4aa5-a88e-83da5b5ba74f","attributeTranslation":"Zastosowanie mogą mieć inne kryteria wykluczenia zdefiniowane w protokole.","language":19,"languageDescription":"Polish"},{"id":11815910,"uuid":"9a28354c-06ee-4aa5-a88e-83da5b5ba74f","attributeTranslation":"Andere in het protocol omschreven exclusiecriteria kunnen van toepassing zijn","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626656,"number":3,"principalExclusionCriteria":"Part A: Evidence of uncontrolled, active infection, requiring systemic antibacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP","principalExclusionCriteriaTranslations":[{"id":11815913,"uuid":"ba7ffcfd-affb-4af1-b8c8-2f0d8c630bbd","attributeTranslation":"Parte A: indicios de infección activa no controlada que requiere tratamiento sistémico antibacteriano, antivírico o antifúngico ≤7 días antes de la administración del PEI.","language":7,"languageDescription":"Spanish"},{"id":11815915,"uuid":"ba7ffcfd-affb-4af1-b8c8-2f0d8c630bbd","attributeTranslation":"Część A: dowody na występowanie niekontrolowanego, czynnego zakażenia, wymagającego ogólnoustrojowego leczenia przeciwbakteryjnego, przeciwwirusowego lub przeciwgrzybiczego na ≤7 dni przed podaniem BP","language":19,"languageDescription":"Polish"},{"id":11815914,"uuid":"ba7ffcfd-affb-4af1-b8c8-2f0d8c630bbd","attributeTranslation":"Deel A: Bewijs van ongecontroleerde, actieve infectie, waarvoor systemische antibacteriële, antivirale of antischimmeltherapie nodig is ≤ 7 dagen vóór toediening van het onderzoeksmiddel","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626657,"number":4,"principalExclusionCriteria":"Part A: Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has NYHA Class III or IV heart failure, symptomatic ventricular arrhythmias, sustained ventricular tachycardia, TdP, the long QT syndrome, pacemaker dependence, or electrocardiographic evidence of acute ischemia","principalExclusionCriteriaTranslations":[{"id":11815917,"uuid":"113bfed5-ab3a-453c-b1ae-7dc46786f880","attributeTranslation":"Część A: zawał mięśnia sercowego w ciągu sześciu miesięcy poprzedzających włączenie do badania, dusznica bolesna klasy większej niż 1, niewydolność serca klasy III lub IV w skali Nowojorskiego Towarzystwa Kardiologicznego (ang. New York Heart Association, NYHA), objawowe zaburzenia rytmu serca, utrzymujący się częstoskurcz komorowy, torsade de pointes, zespół wydłużonego odcinka QT, zależność od rozrusznika serca lub  obserwacje z EKG elektrokardiograficzne wskazujące na ostre niedokrwienie","language":19,"languageDescription":"Polish"},{"id":11815916,"uuid":"113bfed5-ab3a-453c-b1ae-7dc46786f880","attributeTranslation":"Deel A: Myocardinfarct binnen 6 maanden voorafgaand aan de insluiting, erger dan angina pectoris van klasse 1, of hartfalen van NYHA-klasse III of IV, symptomatische ventriculaire aritmieën, aanhoudende ventriculaire tachycardie, TdP, het lange QT-syndroom, pacemakerafhankelijkheid of elektrocardiografisch bewijs van acute ischemie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815918,"uuid":"113bfed5-ab3a-453c-b1ae-7dc46786f880","attributeTranslation":"Parte A: infarto de miocardio en los 6 meses anteriores a la inclusión, mayor que la angina de pecho de clase 1, o tiene insuficiencia cardíaca de clase III o IV según la Asociación Cardiológica de Nueva York (New York Heart Association, NYHA), arritmias ventriculares sintomáticas, taquicardia ventricular sostenida, taquicardia helicoidal, síndrome de QT largo, dependencia de marcapasos o signos electrocardiográficos de isquemia aguda.","language":7,"languageDescription":"Spanish"}]},{"id":1626658,"number":5,"principalExclusionCriteria":"Part A: History of additional risk factors for TdP","principalExclusionCriteriaTranslations":[{"id":11815921,"uuid":"bc150753-7e60-4417-8788-f25e37683fcc","attributeTranslation":"Deel A: Voorgeschiedenis van aanvullende risicofactoren voor TdP","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815919,"uuid":"bc150753-7e60-4417-8788-f25e37683fcc","attributeTranslation":"Parte A: antecedentes de factores de riesgo adicionales para la taquicardia helicoidal.","language":7,"languageDescription":"Spanish"},{"id":11815920,"uuid":"bc150753-7e60-4417-8788-f25e37683fcc","attributeTranslation":"Część A: Obecne w wywiadzie dodatkowe czynniki ryzyka wystąpienia torsade de pointes","language":19,"languageDescription":"Polish"}]},{"id":1626659,"number":6,"principalExclusionCriteria":"Part A: Unstable or severe uncontrolled medical condition or any important medical illness or abnormal laboratory finding","principalExclusionCriteriaTranslations":[{"id":11815924,"uuid":"7406c05c-0f13-447a-a208-94ed6a5a95cd","attributeTranslation":"Część A: Niestabilny lub ciężki niekontrolowany stan internistyczny lub jakiekolwiek istotna choroba internistyczna lub nieprawidłowy wynik badań laboratoryjnych","language":19,"languageDescription":"Polish"},{"id":11815923,"uuid":"7406c05c-0f13-447a-a208-94ed6a5a95cd","attributeTranslation":"Parte A: enfermedades inestables o graves no controladas, o cualquier afección importante o hallazgo analítico anómalo.","language":7,"languageDescription":"Spanish"},{"id":11815922,"uuid":"7406c05c-0f13-447a-a208-94ed6a5a95cd","attributeTranslation":"Deel A: Onstabiele of ernstige ongecontroleerde medische aandoening of een belangrijke medische ziekte of abnormale laboratoriumbevindingen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1626660,"number":7,"principalExclusionCriteria":"Part A: Pregnant or breastfeeding or expecting to conceive children during the study","principalExclusionCriteriaTranslations":[{"id":11815927,"uuid":"62e6183f-8c1a-4f1c-9282-46fac1e35973","attributeTranslation":"Deel A: Is zwanger of geeft borstvoeding of is van plan kinderen te verwekken tijdens het onderzoek","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815925,"uuid":"62e6183f-8c1a-4f1c-9282-46fac1e35973","attributeTranslation":"Część A: Ciąża, karmienie piersią lub oczekiwane poczęcie dziecka w trakcie udziału w badaniu","language":19,"languageDescription":"Polish"},{"id":11815926,"uuid":"62e6183f-8c1a-4f1c-9282-46fac1e35973","attributeTranslation":"Parte A: estar embarazada, en periodo de lactancia o planificar un embarazo durante el estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1626661,"number":8,"principalExclusionCriteria":"Part A: ECOG performance status ≥2","principalExclusionCriteriaTranslations":[{"id":11815929,"uuid":"b9cadd6c-fb80-4b1a-b82a-07618d405260","attributeTranslation":"Deel A: ECOG-prestatiestatus ≥ 2","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815928,"uuid":"b9cadd6c-fb80-4b1a-b82a-07618d405260","attributeTranslation":"Część A: Stan sprawności w skali Wschodniej Grupy Współpracy Onkologicznej (ang. Eastern Cooperative Oncology Group, ECOG) ≥2","language":19,"languageDescription":"Polish"},{"id":11815930,"uuid":"b9cadd6c-fb80-4b1a-b82a-07618d405260","attributeTranslation":"Parte A: estado funcional ≤2 según el Grupo Oncológico Cooperativo de la Costa Este de los EE. UU. (Eastern Cooperative Oncology Group, ECOG).","language":7,"languageDescription":"Spanish"}]},{"id":1626662,"number":9,"principalExclusionCriteria":"Part A: Abnormal organ and marrow function at Screening defined as: a. Neutrophils <1500/mm3; b. Platelet count <100,000/mm3; c. Hemoglobin <9 g/dL; d. Electrolytes (potassium, calcium, magnesium,and phosphorus, using corrected value if low serum albumin level is present) outside the normal limits of the local laboratory; e. Total bilirubin >1.5x ULN (except known Gilbert's syndrome >3x ULN); f.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5x ULN; g. Serum or plasma creatinine > ULN and creatinine clearance (CrCl) <60 mL/min; h. Uncontrolled triglyceride ≥Grade 2 elevations per CTCAE v5.0 (>300 mg/dL or >3.42 mmol/L)","principalExclusionCriteriaTranslations":[{"id":11815933,"uuid":"c370be7c-9971-4396-8e74-771fb6020618","attributeTranslation":"Parte A: funcionamiento anómalo de los órganos o de la médula ósea en la selección definida como: a. Neutrófilos <1500/mm3; b. Cifra de trombocitos <100 000/mm3; c. Hemoglobina <9 g/dl, d. Electrólitos (potasio, calcio, magnesio y fósforo, mediante el valor corregido si existe una concentración baja de seroalbúmina) fuera de los límites normales del laboratorio local; e. Bilirrubina total >1,5 × LSN \n(excepto con síndrome de Gilbert conocido 3 × LSN); f. Aspartato-aminotransferasa (AST) y alanina-aminotransferasa (ALT) >2,5 × LSN; g. Creatinina sérica o plasmática >LSN y aclaramiento de la creatinina (ACr) <60 ml/min; h. Elevaciones de triglicéridos no controladas de grado ≥2 según los criterios terminológicos comunes para acontecimientos adversos (Common Terminology Criteria for Adverse Events, CTCAE) v5.0 (>300 mg/dl o 3,42 mmol/l).","language":7,"languageDescription":"Spanish"},{"id":11815931,"uuid":"c370be7c-9971-4396-8e74-771fb6020618","attributeTranslation":"Deel A: Abnormale orgaan- en beenmergfunctie bij keuring, gedefinieerd als: a. Neutrofielen < 1500/mm3; b. Bloedplaatjesaantal < 100.000/mm3; c. Hemoglobine < 9 g/dl; d. Elektrolyten (kalium, calcium, magnesium en fosfor, met gebruikmaking van de gecorrigeerde waarde indien er sprake is van een laag serumalbuminegehalte) buiten de normale limieten van het lokale laboratorium; e. Totaal\nbilirubine > 1,5 x ULN (behalve bekend syndroom van Gilbert > 3 x ULN); f. Aspartaataminotransferase (ASAT) en alanine-aminotransferase (ALAT) > 2,5 x ULN; g. Serum- of plasmacreatinine > ULN en creatinineklaring (CrCl) < 60 ml/min; h. Ongecontroleerde triglyceridetoename ≥ graad 2 volgens CTCAE v5.0 (> 300 mg/dl of > 3,42 mmol/l)","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815932,"uuid":"c370be7c-9971-4396-8e74-771fb6020618","attributeTranslation":"Część A: Nieprawidłowa czynność narządów i szpiku kostnego podczas badania przesiewowego zdefiniowana jako: a Liczba neutrofili <1500/mm3; b. Liczba płytek <100 000/mm3; c. Stężenie hemoglobiny <9 g/dl; d. Stężenie elektrolitów (potasu, wapnia, magnezu i fosforu przy użyciu skorygowanej wartości, jeśli stężenie albumin w surowicy jest małe) wykraczające poza zakres normy przyjęty przez miejscowe laboratorium; e. Stężenie\nbilirubiny całkowitej >1,5 x GGN (w przypadku rozpoznanego zespołu Gilberta >3 x GGN); f. Aktywność aminotransferazy asparaginianowej (AST) i aminotransferazy alaninowej (ALT) >2,5 x GGN; g. stężenie kreatyniny w surowicy lub w osoczu > GGN i klirens kreatyniny (CrCl) <60 ml/min; h. Nieopanowany wzrost poziomu trójglicerydów stopnia ≥2 wg wspólnych kryteriów terminologicznych dotyczących zdarzeń niepożądanych (ang. Common Terminology Criteria for Adverse Events, CTCAE) w wersji 5.0 (>300 mg/dl lub >3,42 mmol/l)","language":19,"languageDescription":"Polish"}]}]},"endPoint":{"primaryEndPoints":[{"id":1113550,"number":1,"endPoint":"Part A: Frequency and severity of TEAEs and SAEs; time to treatment discontinuation due to TEAE","isPrimary":true,"endPointTranslations":[{"id":11815807,"uuid":"ed4ecc6f-1204-459d-85c2-b1dae3a0705c","attributeTranslation":"Część A: Częstość występowania i nasilenie zdarzeń niepożądanych zaistniałych w trakcie leczenia (TEAE) i ciężkich zdarzeń niepożądanych (CZN); czas do przerwania leczenia z powodu TEAE.","language":19,"languageDescription":"Polish"},{"id":11815805,"uuid":"ed4ecc6f-1204-459d-85c2-b1dae3a0705c","attributeTranslation":"Parte A: frecuencia e intensidad de los AADT y los AAG; tiempo hasta la suspensión del tratamiento debido a AADT.","language":7,"languageDescription":"Spanish"},{"id":11815806,"uuid":"ed4ecc6f-1204-459d-85c2-b1dae3a0705c","attributeTranslation":"Deel A: Frequentie en ernst van TEAE's en SAE's; tijd tot stopzetting van de behandeling vanwege een TEAE","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1113551,"number":2,"endPoint":"Part B: Progression free survival","isPrimary":true,"endPointTranslations":[{"id":11815810,"uuid":"4cf15297-cf91-499e-825c-0921c9240f35","attributeTranslation":"Deel B: Progressievrije overleving","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815809,"uuid":"4cf15297-cf91-499e-825c-0921c9240f35","attributeTranslation":"Parte B: supervivencia sin progresión.","language":7,"languageDescription":"Spanish"},{"id":11815808,"uuid":"4cf15297-cf91-499e-825c-0921c9240f35","attributeTranslation":"Część B: Okres przeżycia bez progresji choroby (ang. Progression-Free Survival, PFS)","language":19,"languageDescription":"Polish"}]},{"id":1113552,"number":3,"endPoint":"OLE: Frequency and severity of TEAEs and SAEs","isPrimary":true,"endPointTranslations":[{"id":11815813,"uuid":"d66d5f03-5536-4b93-8ebf-cd693bb3592e","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Częstość występowania i nasilenie TEAE i CZN","language":19,"languageDescription":"Polish"},{"id":11815811,"uuid":"d66d5f03-5536-4b93-8ebf-cd693bb3592e","attributeTranslation":"EA: frecuencia e intensidad de los AADT y los AAG","language":7,"languageDescription":"Spanish"},{"id":11815812,"uuid":"d66d5f03-5536-4b93-8ebf-cd693bb3592e","attributeTranslation":"OLE: Frequentie en ernst van TEAE's en SAE's","language":37,"languageDescription":"Dutch (Netherlands)"}]}],"secondaryEndPoints":[{"id":1113553,"number":1,"endPoint":"Part A: change from baseline to week 16 in tumor volume","isPrimary":false,"endPointTranslations":[{"id":11815814,"uuid":"34bf4d0f-616c-43c4-80d5-258b4dd29e4c","attributeTranslation":"Część A: zmiana objętości guza w tygodniu 16 wobec wartości wyjściowej","language":19,"languageDescription":"Polish"},{"id":11815815,"uuid":"34bf4d0f-616c-43c4-80d5-258b4dd29e4c","attributeTranslation":"Parte A: cambio desde el inicio hasta la semana 16 en el volumen tumoral.","language":7,"languageDescription":"Spanish"},{"id":11815816,"uuid":"34bf4d0f-616c-43c4-80d5-258b4dd29e4c","attributeTranslation":"Deel A: verandering van baseline tot week 16 in tumorvolume","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1113554,"number":2,"endPoint":"Part B: proportion of subjects with confirmed ORR","isPrimary":false,"endPointTranslations":[{"id":11815819,"uuid":"2287c509-0cde-4f57-88cc-2539b5cd7014","attributeTranslation":"Parte B: proporción de participantes con TRO confirmada.","language":7,"languageDescription":"Spanish"},{"id":11815818,"uuid":"2287c509-0cde-4f57-88cc-2539b5cd7014","attributeTranslation":"Część B: odsetek uczestników, u których wystąpiła potwierdzona odpowiedź obiektywna (ang. Overall Response, OR)","language":19,"languageDescription":"Polish"},{"id":11815817,"uuid":"2287c509-0cde-4f57-88cc-2539b5cd7014","attributeTranslation":"Deel B: percentage onderzoeksdeelnemers met bevestigde ORR","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1113555,"number":3,"endPoint":"Part B: duration of response","isPrimary":false,"endPointTranslations":[{"id":11815820,"uuid":"0e4befe0-c842-443e-a5f4-8cd528692b64","attributeTranslation":"Część B: czas trwania odpowiedzi (ang. Duration of Response, DOR)","language":19,"languageDescription":"Polish"},{"id":11815821,"uuid":"0e4befe0-c842-443e-a5f4-8cd528692b64","attributeTranslation":"Parte B: duración de la respuesta.","language":7,"languageDescription":"Spanish"},{"id":11815822,"uuid":"0e4befe0-c842-443e-a5f4-8cd528692b64","attributeTranslation":"Deel B: duur van de respons","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1113556,"number":4,"endPoint":"Part B: PFS as defined as the time from randomization until the date of radiographic progression by BICR or clinical progression","isPrimary":false,"endPointTranslations":[{"id":11815825,"uuid":"3cd69cc6-48c1-4256-9762-1de765cd27c2","attributeTranslation":"Deel B: PFS gedefinieerd als de tijd vanaf randomisatie tot de datum van radiografische progressie door BICR of klinische progressie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815824,"uuid":"3cd69cc6-48c1-4256-9762-1de765cd27c2","attributeTranslation":"Parte B: SSP, definida como el tiempo desde la aleatorización hasta la fecha de la progresión radiográfica según la RCIE o progresión clínica","language":7,"languageDescription":"Spanish"},{"id":11815823,"uuid":"3cd69cc6-48c1-4256-9762-1de765cd27c2","attributeTranslation":"Część B: Okres przeżycia bez progresji choroby (PFS) zdefiniowany jako czas od randomizacji do daty wystąpienia progresji radiologicznej stwierdzonej przez BICR lub progresji klinicznej","language":19,"languageDescription":"Polish"}]},{"id":1113557,"number":5,"endPoint":"Part B: Change from baseline at Week 24 in estimated tumor volume","isPrimary":false,"endPointTranslations":[{"id":11815826,"uuid":"900d6def-2a43-40da-a747-96d113cfde96","attributeTranslation":"Część B: Zmiana szacowanej objętości guza w tygodniu 24 wobec oceny wyjściowej","language":19,"languageDescription":"Polish"},{"id":11815827,"uuid":"900d6def-2a43-40da-a747-96d113cfde96","attributeTranslation":"Deel B: verandering van baseline in WK24 in geschat tumorvolume","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815828,"uuid":"900d6def-2a43-40da-a747-96d113cfde96","attributeTranslation":"Parte B: cambio con respecto al valor inicial en la semana 24 en el volumen tumoral estimado.","language":7,"languageDescription":"Spanish"}]},{"id":1113558,"number":6,"endPoint":"Part B: Change from baseline to Week 12   in the worst pain intensity (WPI)","isPrimary":false,"endPointTranslations":[{"id":11815831,"uuid":"e89b9c89-b8ba-4fcb-ac2c-92799508e832","attributeTranslation":"Parte B: cambio desde el inicio hasta la semana 12 en la intensidad del mayor dolor (IMD).","language":7,"languageDescription":"Spanish"},{"id":11815829,"uuid":"e89b9c89-b8ba-4fcb-ac2c-92799508e832","attributeTranslation":"Deel B: Verandering van baseline tot week 12 in de ergste pijnintensiteit (worst pain intensity, WPI)","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815830,"uuid":"e89b9c89-b8ba-4fcb-ac2c-92799508e832","attributeTranslation":"Część B: Zmiana oceny największego nasilenia bólu (ang. Worst Pain Intensity, WPI) w tygodniu 28 wobec oceny wyjściowej","language":19,"languageDescription":"Polish"}]},{"id":1113559,"number":7,"endPoint":"Part B: frequency and severity of TEAEs and SAEs","isPrimary":false,"endPointTranslations":[{"id":11815833,"uuid":"c1fff123-a103-46b2-9d14-fa74a666f69b","attributeTranslation":"Parte B: frecuencia e intensidad de los AADT y AAG.","language":7,"languageDescription":"Spanish"},{"id":11815832,"uuid":"c1fff123-a103-46b2-9d14-fa74a666f69b","attributeTranslation":"Deel B: frequentie en ernst van TEAE's en SAE's","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815834,"uuid":"c1fff123-a103-46b2-9d14-fa74a666f69b","attributeTranslation":"Część B: częstość występowania i nasilenie TEAE i CZN","language":19,"languageDescription":"Polish"}]},{"id":1113560,"number":8,"endPoint":"Part B: time to treatment discontinuation due to TEAE","isPrimary":false,"endPointTranslations":[{"id":11815835,"uuid":"9b235b45-4d80-4179-b421-d8a6e6becb85","attributeTranslation":"Deel B: tijd tot stopzetting van de behandeling vanwege een TEAE","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815837,"uuid":"9b235b45-4d80-4179-b421-d8a6e6becb85","attributeTranslation":"Parte B: tiempo hasta la suspensión del tratamiento debido a AADT.","language":7,"languageDescription":"Spanish"},{"id":11815836,"uuid":"9b235b45-4d80-4179-b421-d8a6e6becb85","attributeTranslation":"Część B: czas do przerwania leczenia z powodu TEAE","language":19,"languageDescription":"Polish"}]},{"id":1113561,"number":9,"endPoint":"OLE: PFS as defined as the time of radiographic progression","isPrimary":false,"endPointTranslations":[{"id":11815840,"uuid":"435d122e-9cd8-4e61-9490-15a74ae906a7","attributeTranslation":"OLE: PFS gedefinieerd als de tijd van radiografische progressie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815839,"uuid":"435d122e-9cd8-4e61-9490-15a74ae906a7","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): PFS zdefiniowany jako czas do wystąpienia progresji radiologicznej","language":19,"languageDescription":"Polish"},{"id":11815838,"uuid":"435d122e-9cd8-4e61-9490-15a74ae906a7","attributeTranslation":"EA: SSP definida como el momento de la progresión radiográfica.","language":7,"languageDescription":"Spanish"}]},{"id":1113562,"number":10,"endPoint":"OLE: Proportion of subjects with confirmed ORR (CR and PR) by BICR based on RECIST v1.1","isPrimary":false,"endPointTranslations":[{"id":11815842,"uuid":"abd2b5c8-71e3-46ab-b35c-2e6932113039","attributeTranslation":"OLE: Percentage onderzoeksdeelnemers met bevestigde ORR (CR en PR) volgens BICR op basis van RECIST v1.1","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815843,"uuid":"abd2b5c8-71e3-46ab-b35c-2e6932113039","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): Odsetek uczestników, u których wystąpiła potwierdzona OR [całkowita (ang. Complete Response, CR) lub częściowa (ang. Partial Response, PR)] w ocenie BICR na podstawie kryteriów RECIST w wersji 1.1","language":19,"languageDescription":"Polish"},{"id":11815841,"uuid":"abd2b5c8-71e3-46ab-b35c-2e6932113039","attributeTranslation":"EA: proporción de participantes con TRO confirmada (RC o RP) evaluado por la RCIE según los criterios de evaluación de la respuesta en tumores sólidos (Response Evaluation Criteria in Solid Tumors, RECIST) v1.1.","language":7,"languageDescription":"Spanish"}]},{"id":1113563,"number":11,"endPoint":"OLE: DOR as defined by the time from confirmed OOR (CR or PR) by BICR based on RECIST v1.1 until the earlier of the first documentation of disease progression or death from any cause","isPrimary":false,"endPointTranslations":[{"id":11815844,"uuid":"acbb2cd2-3fc7-435d-8678-4c5d9d08c29f","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): DOR, definiowany jako czas od wystąpienia potwierdzonej OR (CR lub PR) w ocenie BICR na podstawie kryteriów RECIST w wersji 1.1, do pierwszego udokumentowania progresji choroby lub do zgonu z dowolnej przyczyny","language":19,"languageDescription":"Polish"},{"id":11815845,"uuid":"acbb2cd2-3fc7-435d-8678-4c5d9d08c29f","attributeTranslation":"EA: DR definida según el tiempo transcurrido desde la TRO confirmada (RC o RP) por la RCIE según RECIST v1.1 hasta la primera documentación de progresión de la enfermedad o la muerte por cualquier causa, lo que ocurra primero.","language":7,"languageDescription":"Spanish"},{"id":11815846,"uuid":"acbb2cd2-3fc7-435d-8678-4c5d9d08c29f","attributeTranslation":"OLE: DOR gedefinieerd als de tijd vanaf bevestigde OOR (CR of PR) volgens BICR gebaseerd op RECIST v1.1 tot de eerste documentatie van ziekteprogressie of overlijden door welke oorzaak dan ook, afhankelijk van wat zich het eerst voordoet","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1113564,"number":12,"endPoint":"OLE: PFS as defined as the time to radiographic progression as assessed by BICR based on RECIST v1.1, OR clinical progression","isPrimary":false,"endPointTranslations":[{"id":11815847,"uuid":"05126a65-88b4-4c25-829e-c89e5580f87f","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE): PFS zdefiniowany jako czas do wystąpienia progresji radiologicznej w ocenie BICR na podstawie kryteriów RECIST w wersji 1.1 LUB progresji klinicznej","language":19,"languageDescription":"Polish"},{"id":11815848,"uuid":"05126a65-88b4-4c25-829e-c89e5580f87f","attributeTranslation":"OLE: PFS gedefinieerd als de tijd tot radiografische progressie zoals beoordeeld door BICR op basis van RECIST v1.1, OF klinische progressie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815849,"uuid":"05126a65-88b4-4c25-829e-c89e5580f87f","attributeTranslation":"EA: SSP definida como el tiempo hasta la progresión radiográfica evaluada por la RCIE según los criterios RECIST v1.1 O BIEN la progresión clínica.","language":7,"languageDescription":"Spanish"}]},{"id":1113565,"number":13,"endPoint":"OLE: Change from baseline (defined as from the start of AL102 treatment) in − Quality of life as determined by GODDESS DTSS Total Symptom Score − GODDESS DTIS Physical Functioning Domain Score − WPI using GODDESS DTSS Item 1","isPrimary":false,"endPointTranslations":[{"id":11815852,"uuid":"be3afa6e-9e8d-4158-91e1-a73ba46b6ef1","attributeTranslation":"OLE: Verandering ten opzichte van baseline (gedefinieerd als het begin van de AL102-behandeling) in\n− kwaliteit van leven zoals bepaald door de GODDESS DTSS Total Symptom Score\n− de GODDESS DTIS Physical Functioning Domain Score\n− WPI met behulp van de GODDESS DTSS, item 1","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":11815851,"uuid":"be3afa6e-9e8d-4158-91e1-a73ba46b6ef1","attributeTranslation":"EA: cambio con respecto al inicio (definido como el inicio del tratamiento con AL102) en la\n— Calidad de vida, determinada mediante la puntuación total de los síntomas del GODDESS DTSS.\n— Puntuación del dominio de la actividad física de la GODDESS DTIS.\n— IMD con el ítem 1 del cuestionario GODDESS DTSS","language":7,"languageDescription":"Spanish"},{"id":11815850,"uuid":"be3afa6e-9e8d-4158-91e1-a73ba46b6ef1","attributeTranslation":"Okres kontynuacyjny prowadzony metodą otwartej próby (OLE) Zmiana względem puntu wyjściowego (zdefiniowanego jako rozpoczęcie leczenia AL102) w zakresie następujących parametrów\n− ocena jakości życia na podstawie łącznego wyniku w skali oceny objawów guza desmoidalnego (ang.Goddess Desmoid Tumor Symptom Scale, GODDESS DTSS)\n− ocena domeny funkcjonowania fizycznego na podstawie wyniku w skali oceny wpływu guza desmoidalnego GODDESS DTIS\n− ocena WPI przy użyciu pozycji nr 1 ze skali oceny GODDESS","language":19,"languageDescription":"Polish"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2026-12-15","estimatedEndDate":"2026-12-15","estimatedRecruitmentStartDate":"2021-03-15"},"sourceOfMonetarySupport":[{"id":102947,"organisationName":"Immunome, Inc"}],"populationOfTrialSubjects":{"ageRanges":[{"id":384625,"ageRangeCategoryCode":"3","ageRangeCategory":"3"},{"id":384626,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":384624,"ageRangeCategoryCode":"2","ageRangeCategory":"2"}],"ageRangeSecondaryIds":[{"id":384629,"ageRangeCategoryCode":"2","ctAgeRangeCode":"6","ageRangeCategory":"2","ctAgeRange":"6"},{"id":384628,"ageRangeCategoryCode":"4","ctAgeRangeCode":"8","ageRangeCategory":"4","ctAgeRange":"8"},{"id":384627,"ageRangeCategoryCode":"4","ctAgeRangeCode":"7","ageRangeCategory":"4","ctAgeRange":"7"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-07-20","conclusionDate":"2026-07-20","therapeuticAreas":[{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":146571,"medicalCondition":"Progressing desmoid tumors","isConditionRareDisease":true}],"sponsors":[{"id":159407,"primary":true,"publicContacts":[{"id":470554,"type":"Public","functionalName":"Clinical Development Operations","functionalEmailAddress":"info@immunome.com","telephone":"+14259397410","organisation":{"id":537261,"type":"Pharmaceutical company","typeCode":"10","name":"Immunome Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100052125","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":470555,"type":"Scientific","functionalName":"Clinical Development Operations","functionalEmailAddress":"info@immunome.com","telephone":"+14259397410","organisation":{"id":537261,"type":"Pharmaceutical company","typeCode":"10","name":"Immunome Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100052125","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":727606,"organisationAddress":{"id":963026,"organisation":{"id":1006443,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"IQVIA Laboratories LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043195","organisationLocationStatus":"Active"},"address":{"addressId":1083147,"oneLine":"2400 Ellis Road","addressLine1":"2400 Ellis Road","addressLine2":"","addressLine3":"","addressLine4":"","city":"Durham","postcode":"27703-6895","country":840,"countryName":"United States"},"phone":"+441184506016","email":"eu_clinical_trials_information@iqvia.com","isBusinessKeyValidated":true,"businessKey":"ORG-100043195"},"sponsorDuties":[{"id":1127931,"code":"15","value":"tumor tissue analysis; sample processing and storage"}],"phoneNumber":"+441184506016","email":"eu_clinical_trials_information@iqvia.com"},{"id":727617,"organisationAddress":{"id":561350,"organisation":{"id":594022,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Mayo Collaborative Services LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100046687","organisationLocationStatus":"Active"},"address":{"addressId":604550,"oneLine":"3050 Superior Drive Northwest","addressLine1":"3050 Superior Drive Northwest","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rochester","postcode":"55905-1770","country":840,"countryName":"United States"},"phone":"+15072665700","email":"mcl@mayo.edu","isBusinessKeyValidated":true,"businessKey":"ORG-100046687"},"sponsorDuties":[{"id":1127952,"code":"15","value":"AMH testing"}],"phoneNumber":"+15072665700","email":"mcl@mayo.edu"},{"id":727610,"organisationAddress":{"id":963035,"organisation":{"id":1006452,"type":"Pharmaceutical company","typeCode":"10","name":"Mms Holdings Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100010755","organisationLocationStatus":"Active"},"address":{"addressId":1083156,"oneLine":"6880 Commerce Boulevard","addressLine1":"6880 Commerce Boulevard","addressLine2":"","addressLine3":"","addressLine4":"","city":"Canton","postcode":"48187-4457","country":840,"countryName":"United States"},"phone":"7342450310","email":"info@mmsholdings.com","isBusinessKeyValidated":true,"businessKey":"ORG-100010755"},"sponsorDuties":[{"id":1127944,"code":"11"},{"id":1127945,"code":"15","value":"quality control and publishing"}],"phoneNumber":"7342450310","email":"info@mmsholdings.com"},{"id":727619,"organisationAddress":{"id":560482,"organisation":{"id":593148,"type":"Pharmaceutical company","typeCode":"10","name":"Almac Pharma Services Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100000286","organisationLocationStatus":"Active"},"address":{"addressId":603583,"oneLine":"Almac House, 20 Seagoe Industrial Estate","addressLine1":"Almac House","addressLine2":"20 Seagoe Industrial Estate","addressLine3":"","addressLine4":"","city":"Craigavon","postcode":"BT63 5QD","country":827,"countryName":"United Kingdom (Northern Ireland)"},"phone":"+442838332200","email":"info@almacgroup.com","isBusinessKeyValidated":true,"businessKey":"ORG-100000286"},"sponsorDuties":[{"id":1127954,"code":"15","value":"PD analysis"}],"phoneNumber":"+442838332200","email":"info@almacgroup.com"},{"id":727611,"organisationAddress":{"id":561356,"organisation":{"id":594028,"type":"Pharmaceutical company","typeCode":"10","name":"PPD Development LP","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100011560","organisationLocationStatus":"Active"},"address":{"addressId":604557,"oneLine":"3225 Deming Way","addressLine1":"3225 Deming Way","addressLine2":"","addressLine3":"","addressLine4":"","city":"Middleton","postcode":"53562-1408","country":840,"countryName":"United States"},"phone":"+16086627700","email":"Holly.Jaeger@thermofisher.com","isBusinessKeyValidated":true,"businessKey":"ORG-100011560"},"sponsorDuties":[{"id":1127946,"code":"15","value":"PK analysis"}],"phoneNumber":"+16086627700","email":"Holly.Jaeger@thermofisher.com"},{"id":727613,"organisationAddress":{"id":561418,"organisation":{"id":594090,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Medidata Solutions Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100016256","organisationLocationStatus":"Active"},"address":{"addressId":604632,"oneLine":"350 Hudson Street","addressLine1":"350 Hudson Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"New York","postcode":"10014-4504","country":840,"countryName":"United States"},"phone":"+19518212621","email":"info@medidata.com","isBusinessKeyValidated":true,"businessKey":"ORG-100016256"},"sponsorDuties":[{"id":1127948,"code":"7"}],"phoneNumber":"+19518212621","email":"info@medidata.com"},{"id":727608,"organisationAddress":{"id":963038,"organisation":{"id":1006455,"type":"Pharmaceutical company","typeCode":"10","name":"A2-Ai LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100054982","organisationLocationStatus":"Active"},"address":{"addressId":1083159,"oneLine":"2723 South State Street Suite 310","addressLine1":"2723 South State Street Suite 310","addressLine2":"","addressLine3":"","addressLine4":"","city":"Ann Arbor","postcode":"48104-6188","country":840,"countryName":"United States"},"phone":"8604220727","email":"qa@a2-ai.com","isBusinessKeyValidated":true,"businessKey":"ORG-100054982"},"sponsorDuties":[{"id":1127941,"code":"15","value":"Clinical Pharmacology, Pharmacokinetics, Noncompartmental Analysis"}],"phoneNumber":"8604220727","email":"qa@a2-ai.com"},{"id":727618,"organisationAddress":{"id":561364,"organisation":{"id":594036,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Tempus Labs Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100044006","organisationLocationStatus":"Active"},"address":{"addressId":604565,"oneLine":"600 West Chicago Avenue, Suite 510","addressLine1":"600 West Chicago Avenue","addressLine2":"Suite 510","addressLine3":"","addressLine4":"","city":"Chicago","postcode":"60654-2282","country":840,"countryName":"United States"},"phone":"+18335144187","email":"support@tempus.com","isBusinessKeyValidated":true,"businessKey":"ORG-100044006"},"sponsorDuties":[{"id":1127953,"code":"15","value":"Genomic analysis"}],"phoneNumber":"+18335144187","email":"support@tempus.com"},{"id":727615,"organisationAddress":{"id":560437,"organisation":{"id":593102,"type":"Pharmaceutical company","typeCode":"10","name":"Imaging Endpoints II LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100045399","organisationLocationStatus":"Active"},"address":{"addressId":603534,"oneLine":"7150 East Camelback Road Ste 120","addressLine1":"7150 East Camelback Road Ste 120","addressLine2":"","addressLine3":"","addressLine4":"","city":"Scottsdale","postcode":"85251-1240","country":840,"countryName":"United States"},"phone":"+4803143070","email":"thecure@imagingendpoints.com","isBusinessKeyValidated":true,"businessKey":"ORG-100045399"},"sponsorDuties":[{"id":1127950,"code":"15","value":"Medical image analysis/review - X-ray, MRI, ultrasound, etc."}],"phoneNumber":"+4803143070","email":"thecure@imagingendpoints.com"},{"id":727616,"organisationAddress":{"id":561411,"organisation":{"id":594083,"type":"Pharmaceutical company","typeCode":"10","name":"Alcura Health Espana S.A.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100020590","organisationLocationStatus":"Active"},"address":{"addressId":604623,"oneLine":"Calle Marie Curie 54","addressLine1":"Calle Marie Curie 54","addressLine2":"","addressLine3":"","addressLine4":"","city":"Viladecans","postcode":"08840","country":2027,"countryName":"Spain"},"phone":"+34937360870","email":"projectmanagement@alcura-health.es","isBusinessKeyValidated":true,"businessKey":"ORG-100020590"},"sponsorDuties":[{"id":1127951,"code":"14"}],"phoneNumber":"+34937360870","email":"projectmanagement@alcura-health.es"},{"id":727612,"organisationAddress":{"id":963017,"organisation":{"id":1006434,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Iqvia Laboratories Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042527","organisationLocationStatus":"Active"},"address":{"addressId":1083137,"oneLine":"3 Forbury Place, 23 Forbury Road","addressLine1":"3 Forbury Place","addressLine2":"23 Forbury Road","addressLine3":"","addressLine4":"","city":"Reading","postcode":"RG1 3JH","country":826,"countryName":"United Kingdom"},"phone":"+441184506016","email":"eu_clinical_trials_information@iqvia.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042527"},"sponsorDuties":[{"id":1127947,"code":"15","value":"tumor tissue analysis; sample processing and storage"}],"phoneNumber":"+441184506016","email":"eu_clinical_trials_information@iqvia.com"},{"id":727609,"organisationAddress":{"id":963043,"organisation":{"id":1006460,"type":"Industry","typeCode":"3","name":"Open Health","commercial":true,"isBusinessKeyValidated":false,"businessKey":"ORL-000018989","organisationLocationStatus":"Active"},"address":{"addressId":1083165,"oneLine":"20 Old Bailey","addressLine1":"20 Old Bailey","addressLine2":"","addressLine3":"","addressLine4":"","city":"London","postcode":"EC4M 7AN","country":826,"countryName":"United Kingdom"},"phone":"+4402039870400","email":"quality@openhealthgroup.com","isBusinessKeyValidated":false,"businessKey":"ORL-000018989"},"sponsorDuties":[{"id":1127942,"code":"10"},{"id":1127943,"code":"15","value":"ePRO analysis"}],"phoneNumber":"+4402039870400","email":"quality@openhealthgroup.com"},{"id":727614,"organisationAddress":{"id":963032,"organisation":{"id":1006449,"type":"Pharmaceutical company","typeCode":"10","name":"Edetek Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100045957","organisationLocationStatus":"Active"},"address":{"addressId":1083153,"oneLine":"101 College Road East Floor 2","addressLine1":"101 College Road East Floor 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Princeton","postcode":"08540-6775","country":840,"countryName":"United States"},"phone":"6097200888","email":"Wei.Kong@edetek.com","isBusinessKeyValidated":true,"businessKey":"ORG-100045957"},"sponsorDuties":[{"id":1127949,"code":"15","value":"PD analysis"}],"phoneNumber":"6097200888","email":"Wei.Kong@edetek.com"},{"id":727607,"organisationAddress":{"id":561374,"organisation":{"id":594046,"type":"Pharmaceutical company","typeCode":"10","name":"IQVIA Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008655","organisationLocationStatus":"Active"},"address":{"addressId":604578,"oneLine":"3 Forbury Place, 23 Forbury Road","addressLine1":"3 Forbury Place","addressLine2":"23 Forbury Road","addressLine3":"","addressLine4":"","city":"Reading","postcode":"RG1 3JH","country":826,"countryName":"United Kingdom"},"phone":"+441184506016","email":"eu_clinical_trials_information@iqvia.com","isBusinessKeyValidated":true,"businessKey":"ORG-100008655"},"sponsorDuties":[{"id":1127932,"code":"1"},{"id":1127933,"code":"10"},{"id":1127934,"code":"11"},{"id":1127935,"code":"12"},{"id":1127936,"code":"2"},{"id":1127937,"code":"3"},{"id":1127938,"code":"5"},{"id":1127939,"code":"6"},{"id":1127940,"code":"8"}],"phoneNumber":"+441184506016","email":"eu_clinical_trials_information@iqvia.com"}],"organisation":{"id":1064690,"type":"Pharmaceutical company","typeCode":"10","name":"Immunome Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100052125","organisationLocationStatus":"Active"},"addresses":[{"id":1018306,"organisation":{"id":1064690,"type":"Pharmaceutical company","typeCode":"10","name":"Immunome Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100052125","organisationLocationStatus":"Active"},"address":{"addressId":1149001,"oneLine":"18702 North Creek Parkway Suite 100","addressLine1":"18702 North Creek Parkway Suite 100","addressLine2":"","addressLine3":"","addressLine4":"","city":"Bothell","postcode":"98011-8019","country":840,"countryName":"United States"},"phone":"4259397410","email":"info&#64;immunome.com","isBusinessKeyValidated":true,"businessKey":"LOC-100091736"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This is a phase II/III trial, therefore it falls under category 2","partOneTherapeuticAreas":[{"id":1221606,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":433375,"comments":"AL102, AL102","productRoleCode":"1","productRoleName":"Test","products":[{"id":583262,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11591075","productPharmForm":"CAPSULE","euMpNumber":"PRD11584484","prodAuthStatus":1,"prodName":"AL102","pharmForm":"CAPSULE","sponsorProductCode":"AL102","activeSubstanceName":"VAREGACESTAT","euSubstNumber":"SUB218539","nameOrg":"IMMUNOME INC","productSubstances":[{"productPk":"11591075","substancePk":"404769","nameOrg":"IMMUNOME INC","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"VAREGACESTAT","substanceEvCode":"SUB218539","synonyms":["BMS-986115","(2R,3S)-N1-[(3S)-5-(3-Fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide","AL102"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"4","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"999","maxTreatmentPeriod":999,"timeUnitCode":"1","otherMedicinalProduct":"Chemical","evCode":"PRD11584484","sponsorProductCodeEdit":"AL102","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"AL102","jsonActiveSubstanceNames":"varegacestat","pharmaceuticalFormDisplay":"CAPSULE"},{"id":583263,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11591074","productPharmForm":"CAPSULE","euMpNumber":"PRD11584202","prodAuthStatus":1,"prodName":"AL102","pharmForm":"CAPSULE","sponsorProductCode":"AL102","activeSubstanceName":"VAREGACESTAT","euSubstNumber":"SUB218539","nameOrg":"IMMUNOME INC","productSubstances":[{"productPk":"11591074","substancePk":"404769","nameOrg":"IMMUNOME INC","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"VAREGACESTAT","substanceEvCode":"SUB218539","synonyms":["BMS-986115","(2R,3S)-N1-[(3S)-5-(3-Fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide","AL102"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1.2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"999","maxTreatmentPeriod":999,"timeUnitCode":"1","otherMedicinalProduct":"Chemical","evCode":"PRD11584202","sponsorProductCodeEdit":"AL102","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"AL102","jsonActiveSubstanceNames":"varegacestat","pharmaceuticalFormDisplay":"CAPSULE"}]},{"id":433376,"comments":"Placebo capsule","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":583264,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Placebo capsule","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Placebo capsule","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":304742,"mscId":38619,"mscInfo":{"id":38619,"clinicalTrialId":16866,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2024-10-23","toDate":"2024-10-23","isProposedRms":false,"expressDecision":"unwilling","countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2024-11-12","trialStatus":"Authorised","trialPeriod":[{"id":42068,"trialStartDate":"2022-01-27","fromDate":"2024-11-13"},{"id":42069,"trialStartDate":"2022-01-27","fromDate":"2024-11-13"}],"trialRecruitmentPeriod":[{"id":55338,"recruitmentStartDate":"2022-02-07","fromDate":"2024-11-13"},{"id":55339,"recruitmentStartDate":"2022-02-07","fromDate":"2024-11-13"},{"id":55340,"recruitmentStartDate":"2022-02-07","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-13"},{"id":55341,"recruitmentStartDate":"2022-02-07","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-13"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":57134,"trialStartDate":"2022-01-27","fromDate":"2024-11-13"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2022-02-07","recruitmentEndDate":"2024-02-14"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55805,"mscId":38619,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-08T11:22:47.978"},{"id":65449,"mscId":38619,"trialStatus":"Authorised","trialStatusDate":"2024-11-12T08:18:35.607"}],"applicationTypeMsc":"1","mscName":"Spain","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-18","decision":"authorized","decisionDate":"2024-11-12"},"decisionDate":"2024-11-12","recruitmentSubjectCount":18,"trialSites":[{"id":2119134,"organisationAddressInfo":{"id":599855,"organisation":{"id":632721,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitari Vall D Hebron","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030781","organisationLocationStatus":"Active"},"address":{"addressId":647583,"oneLine":"Passeig De La Vall D'Hebron 119-129","addressLine1":"Passeig De La Vall D'Hebron 119-129","addressLine2":"","addressLine3":"","addressLine4":"","city":"Barcelona","postcode":"08035","country":2027,"countryName":"Spain"},"phone":"+34934664350","email":"cvalverde@vhio.net","isBusinessKeyValidated":true,"businessKey":"ORG-100030781"},"personInfo":{"id":2351612,"firstName":"Claudia Maria","lastName":"Valverde Morales","telephone":"+34934664350","email":"cvalverde@vhio.net","title":"1"},"departmentName":"Oncology"},{"id":2119137,"organisationAddressInfo":{"id":599858,"organisation":{"id":632724,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Miguel Servet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041170","organisationLocationStatus":"Active"},"address":{"addressId":647586,"oneLine":"Paseo De Isabel La Catolica 1-3","addressLine1":"Paseo De Isabel La Catolica 1-3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Zaragoza","postcode":"50009","country":2027,"countryName":"Spain"},"phone":"+34976218131","email":"jmtrufero@seom.org","isBusinessKeyValidated":true,"businessKey":"ORG-100041170"},"personInfo":{"id":2351615,"firstName":"Javier","lastName":"Martinez Trufero","telephone":"+34976218131","email":"jmtrufero@seom.org","title":"1"},"departmentName":"Oncology"},{"id":2119138,"organisationAddressInfo":{"id":599856,"organisation":{"id":632722,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Fundacion Jimenez Diaz","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028994","organisationLocationStatus":"Active"},"address":{"addressId":647584,"oneLine":"Avenida De Los Reyes Catolicos 2","addressLine1":"Avenida De Los Reyes Catolicos 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28040","country":2027,"countryName":"Spain"},"phone":"+34680811609","email":"nhindi@atbsarc.org","isBusinessKeyValidated":true,"businessKey":"ORG-100028994"},"personInfo":{"id":2351616,"firstName":"Nadia","lastName":"Hindi Muñiz","telephone":"+34680811609","email":"nhindi@atbsarc.org","title":"1"},"departmentName":"Oncology"},{"id":2119136,"organisationAddressInfo":{"id":599859,"organisation":{"id":632725,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"},"address":{"addressId":647587,"oneLine":"Avenida De Cordoba Sn","addressLine1":"Avenida De Cordoba Sn","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28041","country":2027,"countryName":"Spain"},"phone":"+34913908307","email":"enrique.gonzalezbilla@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100028548"},"personInfo":{"id":2351614,"firstName":"Enrique","lastName":"Gonzalez Billalabeitia","telephone":"+34913908307","email":"enrique.gonzalezbilla@gmail.com","title":"1"},"departmentName":"Oncology"},{"id":2119135,"organisationAddressInfo":{"id":599857,"organisation":{"id":632723,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Catala D'oncologia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030394","organisationLocationStatus":"Active"},"address":{"addressId":647585,"oneLine":"Avinguda De La Gran Via De L'hospitalet 199-203","addressLine1":"Avinguda De La Gran Via De L'hospitalet 199-203","addressLine2":"","addressLine3":"","addressLine4":"","city":"L'hospitalet De Llobregat","postcode":"08908","country":2027,"countryName":"Spain"},"phone":"+34932607739","email":"garciadelmuro@iconcologia.net","isBusinessKeyValidated":true,"businessKey":"ORG-100030394"},"personInfo":{"id":2351613,"firstName":"Xavier","lastName":"Garcia del Muro Solans","telephone":"+34932607739","email":"garciadelmuro@iconcologia.net","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":304744,"mscId":38617,"mscInfo":{"id":38617,"clinicalTrialId":16866,"countryOrganisationId":2013,"reportingStatusCode":"Authorised","fromDate":"2024-10-23","toDate":"2024-10-23","isProposedRms":false,"expressDecision":"unwilling","countryName":"Germany","organisationInfo":{},"firstDecisionDate":"2024-11-13","trialStatus":"Authorised","trialPeriod":[{"id":42302,"trialStartDate":"2023-05-31","fromDate":"2024-11-14"},{"id":42303,"trialStartDate":"2023-05-31","fromDate":"2024-11-14"}],"trialRecruitmentPeriod":[{"id":55712,"recruitmentStartDate":"2023-07-04","fromDate":"2024-11-14"},{"id":55713,"recruitmentStartDate":"2023-07-04","fromDate":"2024-11-14"},{"id":55714,"recruitmentStartDate":"2023-07-04","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-14"},{"id":55715,"recruitmentStartDate":"2023-07-04","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-14"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":57503,"trialStartDate":"2023-05-31","fromDate":"2024-11-14"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2023-07-04","recruitmentEndDate":"2024-02-14"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55803,"mscId":38617,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-08T11:22:47.953"},{"id":69013,"mscId":38617,"trialStatus":"Authorised","trialStatusDate":"2024-11-13T09:16:39.785"}],"applicationTypeMsc":"1","mscName":"Germany","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-26","decision":"authorized","decisionDate":"2024-11-13"},"decisionDate":"2024-11-13","recruitmentSubjectCount":11,"trialSites":[{"id":2119142,"organisationAddressInfo":{"id":598583,"organisation":{"id":631412,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"HELIOS Klinikum Berlin-Buch GmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100025249","organisationLocationStatus":"Active"},"address":{"addressId":646144,"oneLine":"Schwanebecker Chaussee 50, Buch","addressLine1":"Schwanebecker Chaussee 50","addressLine2":"Buch","addressLine3":"","addressLine4":"","city":"Berlin","postcode":"13125","country":2013,"countryName":"Germany"},"phone":"+4930940154850","email":"peter.reichardt@helios-gesundheit.de","isBusinessKeyValidated":true,"businessKey":"ORG-100025249"},"personInfo":{"id":2351620,"firstName":"Peter","lastName":"Reichardt","telephone":"+4930940154850","email":"peter.reichardt@helios-gesundheit.de","title":"2"},"departmentName":"N/A"},{"id":2119141,"organisationAddressInfo":{"id":598620,"organisation":{"id":631449,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Mannheim GmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028993","organisationLocationStatus":"Active"},"address":{"addressId":646191,"oneLine":"Theodor-Kutzer-Ufer 1-3, Wohlgelegen","addressLine1":"Theodor-Kutzer-Ufer 1-3","addressLine2":"Wohlgelegen","addressLine3":"","addressLine4":"","city":"Mannheim","postcode":"68167","country":2013,"countryName":"Germany"},"phone":"+496213832580","email":"bernd.kasper@umm.de","isBusinessKeyValidated":true,"businessKey":"ORG-100028993"},"personInfo":{"id":2351619,"firstName":"Bernd","lastName":"Kasper","telephone":"+496213832580","email":"bernd.kasper@umm.de","title":"2"},"departmentName":"N/A"}],"applicationStatusCode":"Authorised"},{"id":304740,"mscId":38618,"mscInfo":{"id":38618,"clinicalTrialId":16866,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2024-10-23","toDate":"2024-10-23","isProposedRms":false,"expressDecision":"unwilling","countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2024-11-19","trialStatus":"Authorised","trialPeriod":[{"id":43340,"trialStartDate":"2023-11-07","fromDate":"2024-11-22"},{"id":43341,"trialStartDate":"2023-11-07","fromDate":"2024-11-22"}],"trialRecruitmentPeriod":[{"id":56968,"recruitmentStartDate":"2023-11-08","fromDate":"2024-11-22"},{"id":56967,"recruitmentStartDate":"2023-11-08","fromDate":"2024-11-22"},{"id":56969,"recruitmentStartDate":"2023-11-08","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-22"},{"id":56970,"recruitmentStartDate":"2023-11-08","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-22"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":58890,"trialStartDate":"2023-11-07","fromDate":"2024-11-22"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2023-11-08","recruitmentEndDate":"2024-02-14"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55804,"mscId":38618,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-08T11:22:47.966"},{"id":69864,"mscId":38618,"trialStatus":"Authorised","trialStatusDate":"2024-11-19T23:59:59"}],"applicationTypeMsc":"1","mscName":"Italy","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-16","decision":"authorized","decisionDate":"2024-11-19"},"decisionDate":"2024-11-19","recruitmentSubjectCount":9,"trialSites":[{"id":2119131,"organisationAddressInfo":{"id":597399,"organisation":{"id":630221,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione IRCCS Istituto Nazionale Dei Tumori","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008982","organisationLocationStatus":"Active"},"address":{"addressId":644836,"oneLine":"Via Giacomo Venezian 1","addressLine1":"Via Giacomo Venezian 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20133","country":2018,"countryName":"Italy"},"phone":"+39223902803","email":"elena.palassini@istitutotumori.mi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100008982"},"personInfo":{"id":2351609,"firstName":"Elena","lastName":"Palassini","telephone":"+39223902803","email":"elena.palassini@istitutotumori.mi.it","title":"1"},"departmentName":"Medical Oncology"},{"id":2119132,"organisationAddressInfo":{"id":597396,"organisation":{"id":630218,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041737","organisationLocationStatus":"Active"},"address":{"addressId":644833,"oneLine":"Via Alvaro Del Portillo N 200","addressLine1":"Via Alvaro Del Portillo N 200","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00128","country":2018,"countryName":"Italy"},"phone":"+396225411123","email":"b.vincenzi@policlinicocampus.it","isBusinessKeyValidated":true,"businessKey":"ORG-100041737"},"personInfo":{"id":2351610,"firstName":"Bruno","lastName":"Vincenzi","telephone":"+396225411123","email":"b.vincenzi@policlinicocampus.it","title":"1"},"departmentName":"Medical Oncology"}],"applicationStatusCode":"Authorised"},{"id":304745,"mscId":38621,"mscInfo":{"id":38621,"clinicalTrialId":16866,"countryOrganisationId":2031,"reportingStatusCode":"Authorised","fromDate":"2024-10-23","toDate":"2024-10-23","isProposedRms":false,"expressDecision":"unwilling","countryName":"Poland","organisationInfo":{},"firstDecisionDate":"2024-12-09","trialStatus":"Authorised","trialPeriod":[{"id":45394,"trialStartDate":"2023-01-10","fromDate":"2024-12-10"},{"id":45395,"trialStartDate":"2023-01-10","fromDate":"2024-12-10"}],"trialRecruitmentPeriod":[{"id":60020,"recruitmentStartDate":"2023-01-30","recruitmentEndDate":"2024-02-14","fromDate":"2024-12-10"},{"id":60021,"recruitmentStartDate":"2023-01-30","recruitmentEndDate":"2024-02-14","fromDate":"2024-12-10"},{"id":60018,"recruitmentStartDate":"2023-01-30","fromDate":"2024-12-10"},{"id":60019,"recruitmentStartDate":"2023-01-30","fromDate":"2024-12-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":62020,"trialStartDate":"2023-01-10","fromDate":"2024-12-10"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2023-01-30","recruitmentEndDate":"2024-02-14"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55807,"mscId":38621,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-08T11:22:48.007"},{"id":71611,"mscId":38621,"trialStatus":"Authorised","trialStatusDate":"2024-12-09T09:21:37.811"}],"applicationTypeMsc":"1","mscName":"Poland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-29","decision":"authorized","decisionDate":"2024-12-09"},"decisionDate":"2024-12-09","recruitmentSubjectCount":20,"trialSites":[{"id":2119143,"organisationAddressInfo":{"id":592160,"organisation":{"id":624950,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009191","organisationLocationStatus":"Active"},"address":{"addressId":638979,"oneLine":"Ul. Wilhelma Konrada Roentgena 5","addressLine1":"Ul. Wilhelma Konrada Roentgena 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Warsaw","postcode":"02-781","country":2031,"countryName":"Poland"},"phone":"+48501153384","email":"piotr.rutkowski@nio.gov.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100009191"},"personInfo":{"id":2351621,"firstName":"Piotr","lastName":"Rutkowski","telephone":"+48501153384","email":"piotr.rutkowski@nio.gov.pl","title":"2"},"departmentName":"Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków"}],"applicationStatusCode":"Authorised"},{"id":304743,"mscId":38620,"mscInfo":{"id":38620,"clinicalTrialId":16866,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2024-10-23","toDate":"2024-10-23","isProposedRms":true,"expressDecision":"willing","countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2024-10-30","trialStatus":"Authorised","trialPeriod":[{"id":40858,"trialStartDate":"2022-01-26","fromDate":"2024-11-01"},{"id":40859,"trialStartDate":"2022-01-26","fromDate":"2024-11-01"}],"trialRecruitmentPeriod":[{"id":53529,"recruitmentStartDate":"2022-02-09","fromDate":"2024-11-01"},{"id":53530,"recruitmentStartDate":"2022-02-09","fromDate":"2024-11-01"},{"id":53531,"recruitmentStartDate":"2022-02-09","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-01"},{"id":53532,"recruitmentStartDate":"2022-02-09","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-01"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":55253,"trialStartDate":"2022-01-26","fromDate":"2024-11-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2022-02-09","recruitmentEndDate":"2024-02-14"},"isWillingAtDayThreeView":true,"clinicalTrialStatusHistory":[{"id":59255,"mscId":38620,"trialStatus":"Authorised","trialStatusDate":"2024-10-30T11:32:55.59"},{"id":55806,"mscId":38620,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-08T11:22:47.993"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-23","decision":"authorized","decisionDate":"2024-10-30"},"decisionDate":"2024-10-30","recruitmentSubjectCount":4,"trialSites":[{"id":2119140,"organisationAddressInfo":{"id":613102,"organisation":{"id":650774,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Netherlands Cancer Institute","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100009158","organisationLocationStatus":"Active"},"address":{"addressId":662526,"oneLine":"Plesmanlaan 121","addressLine1":"Plesmanlaan 121","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1066 CX","country":2029,"countryName":"Netherlands"},"phone":"312403619166","email":"w.vd.graaf@nki.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100009158"},"personInfo":{"id":2351618,"firstName":"Winette","lastName":"van der Graaf","telephone":"312403619166","email":"w.vd.graaf@nki.nl","title":"2"},"departmentName":"Oncology"},{"id":2119139,"organisationAddressInfo":{"id":613095,"organisation":{"id":650767,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008976","organisationLocationStatus":"Active"},"address":{"addressId":662518,"oneLine":"Dr. Molewaterplein 60","addressLine1":"Dr. Molewaterplein 60","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rotterdam","postcode":"3015 GJ","country":2029,"countryName":"Netherlands"},"phone":"31107034447","email":"h.verheul@erasmusmc.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100008976"},"personInfo":{"id":2351617,"firstName":"Hendrik Marinus Willem","lastName":"Verheul","telephone":"31107034447","email":"h.verheul@erasmusmc.nl","title":"2"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":304741,"mscId":38616,"mscInfo":{"id":38616,"clinicalTrialId":16866,"countryOrganisationId":2002,"reportingStatusCode":"Authorised","fromDate":"2024-10-23","toDate":"2024-10-23","isProposedRms":false,"expressDecision":"unwilling","countryName":"Belgium","organisationInfo":{},"firstDecisionDate":"2024-10-30","trialStatus":"Authorised","trialPeriod":[{"id":41584,"trialStartDate":"2023-07-26","fromDate":"2024-11-08"},{"id":41585,"trialStartDate":"2023-07-26","fromDate":"2024-11-08"},{"id":41586,"trialStartDate":"2023-07-26","fromDate":"2024-11-08"}],"trialRecruitmentPeriod":[{"id":54481,"recruitmentStartDate":"2023-10-03","fromDate":"2024-11-08"},{"id":54482,"recruitmentStartDate":"2023-10-03","fromDate":"2024-11-08"},{"id":54483,"recruitmentStartDate":"2023-10-03","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-08"},{"id":54484,"recruitmentStartDate":"2023-10-03","recruitmentEndDate":"2024-02-14","fromDate":"2024-11-08"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":56316,"trialStartDate":"2023-07-26","fromDate":"2024-11-08"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2023-10-03","recruitmentEndDate":"2024-02-14"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":59291,"mscId":38616,"trialStatus":"Authorised","trialStatusDate":"2024-10-30T14:44:08.976"},{"id":55802,"mscId":38616,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-08T11:22:47.931"}],"applicationTypeMsc":"1","mscName":"Belgium","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-07-02","decision":"authorized","decisionDate":"2024-10-30"},"decisionDate":"2024-10-30","recruitmentSubjectCount":1,"trialSites":[{"id":2119133,"organisationAddressInfo":{"id":599147,"organisation":{"id":631977,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Ziekenhuis Gent","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100021542","organisationLocationStatus":"Active"},"address":{"addressId":646769,"oneLine":"Corneel Heymanslaan 10","addressLine1":"Corneel Heymanslaan 10","addressLine2":"","addressLine3":"","addressLine4":"","city":"Gent","postcode":"9000","country":2002,"countryName":"Belgium"},"phone":"+32479454255","email":"lore.lapeire@ugent.be","isBusinessKeyValidated":true,"businessKey":"ORG-100021542"},"personInfo":{"id":2351611,"firstName":"Lore","lastName":"Lapeire","telephone":"+32479454255","email":"lore.lapeire@ugent.be","title":"2"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":29599,"type":"INITIAL","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2024-10-08","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-30"},"partIIInfo":[{"id":150377,"mscId":38616,"mscInfo":{"id":38616,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-30","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"},{"id":150378,"mscId":38617,"mscInfo":{"id":38617,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-11-11","decision":"authorized","decisionDate":"2024-11-13","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-11-13"},"applicationStatusCode":"Authorised"},{"id":150379,"mscId":38618,"mscInfo":{"id":38618,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-11-14","decision":"authorized","decisionDate":"2024-11-19","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-11-19"},"applicationStatusCode":"Authorised"},{"id":150380,"mscId":38619,"mscInfo":{"id":38619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-11-12","decision":"authorized","decisionDate":"2024-11-12","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-11-12"},"applicationStatusCode":"Authorised"},{"id":150381,"mscId":38620,"mscInfo":{"id":38620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-30","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"},{"id":150382,"mscId":38621,"mscInfo":{"id":38621,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-12-03","decision":"authorized","decisionDate":"2024-12-09","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-12-09"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-10-30","ctMSCsByApplication":[{"id":38616,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":38617,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":38618,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":38620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":38621,"mscName":"Poland","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":44221,"applicationId":29599,"mscId":38620,"mscName":"Netherlands","decisionDate":"2024-10-30T11:32:56.31","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":150381,"part1Id":60335,"applicationType":"INITIAL","isRMS":true},{"id":50065,"applicationId":29599,"mscId":38621,"mscName":"Poland","decisionDate":"2024-12-09T09:21:38.675","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":150382,"part1Id":60335,"applicationType":"INITIAL","isRMS":false},{"id":44300,"applicationId":29599,"mscId":38616,"mscName":"Belgium","decisionDate":"2024-10-30T14:44:09.822","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":150377,"part1Id":60335,"applicationType":"INITIAL","isRMS":false},{"id":47518,"applicationId":29599,"mscId":38618,"mscName":"Italy","decisionDate":"2024-11-19T00:00:00","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":150379,"part1Id":60335,"applicationType":"INITIAL","isRMS":false},{"id":46397,"applicationId":29599,"mscId":38617,"mscName":"Germany","decisionDate":"2024-11-13T09:16:40.394","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":150378,"part1Id":60335,"applicationType":"INITIAL","isRMS":false},{"id":46158,"applicationId":29599,"mscId":38619,"mscName":"Spain","decisionDate":"2024-11-12T08:18:36.668","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":150380,"part1Id":60335,"applicationType":"INITIAL","isRMS":false}]},{"id":50744,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2025-03-18","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-30"},"partIIInfo":[{"id":190365,"mscId":38619,"mscInfo":{"id":38619,"mscName":"Spain","countryOrganisationId":2027,"decision":"authorized","decisionDate":"2024-11-12","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-11-12"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-03-18","ctMSCsByApplication":[{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":62649,"applicationId":50744,"mscId":38619,"mscName":"Spain","decisionDate":"2025-03-18T12:42:11.113","decision":"authorized","eventType":"decision","part2Id":190365,"part1Id":78194,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":53012,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2025-04-10","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":199342,"mscId":38620,"mscInfo":{"id":38620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-28","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-30","ctMSCsByApplication":[{"id":38620,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":69354,"applicationId":53012,"mscId":38620,"mscName":"Netherlands","decisionDate":"2025-04-30T13:48:53.88","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":199342,"part1Id":81726,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":55390,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2025-06-13","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-25"},"partIIInfo":[{"id":235677,"mscId":38617,"mscInfo":{"id":38617,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-11","decision":"authorized","decisionDate":"2024-11-13","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-11-13"},"applicationStatusCode":"Authorised"},{"id":230427,"mscId":38620,"mscInfo":{"id":38620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-25","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"},{"id":220490,"mscId":38618,"mscInfo":{"id":38618,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-11","decision":"authorized","decisionDate":"2024-11-19","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-11-19"},"applicationStatusCode":"Authorised"},{"id":220488,"mscId":38616,"mscInfo":{"id":38616,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-21","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"},{"id":220493,"mscId":38621,"mscInfo":{"id":38621,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-14","decision":"authorized","decisionDate":"2024-12-09","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-12-09"},"applicationStatusCode":"Authorised"},{"id":220491,"mscId":38619,"mscInfo":{"id":38619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-15","decision":"authorized","decisionDate":"2024-11-12","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-11-12"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-08-25","ctMSCsByApplication":[{"id":38617,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":38620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":38618,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":38616,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":38621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":86731,"applicationId":55390,"mscId":38619,"mscName":"Spain","decisionDate":"2025-08-28T08:42:35.816","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":220491,"part1Id":97682,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":88982,"applicationId":55390,"mscId":38617,"mscName":"Germany","decisionDate":"2025-09-12T08:21:42.869","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":235677,"part1Id":97682,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":86995,"applicationId":55390,"mscId":38616,"mscName":"Belgium","decisionDate":"2025-08-29T11:42:38.34","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":220488,"part1Id":97682,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":89202,"applicationId":55390,"mscId":38618,"mscName":"Italy","decisionDate":"2025-09-12T16:33:01.705","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":220490,"part1Id":97682,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":87279,"applicationId":55390,"mscId":38621,"mscName":"Poland","decisionDate":"2025-09-01T13:00:45.858","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":220493,"part1Id":97682,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":86111,"applicationId":55390,"mscId":38620,"mscName":"Netherlands","decisionDate":"2025-08-25T15:09:53.039","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":230427,"part1Id":97682,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":67197,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2025-11-19","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-18"},"partIIInfo":[{"id":248329,"mscId":38619,"mscInfo":{"id":38619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-12","decision":"authorized","decisionDate":"2024-11-12","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-11-12"},"applicationStatusCode":"Authorised"},{"id":248332,"mscId":38621,"mscInfo":{"id":38621,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-16","decision":"authorized","decisionDate":"2024-12-09","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-12-09"},"applicationStatusCode":"Authorised"},{"id":248331,"mscId":38617,"mscInfo":{"id":38617,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-13","decision":"authorized","decisionDate":"2024-11-13","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-11-13"},"applicationStatusCode":"Authorised"},{"id":248327,"mscId":38618,"mscInfo":{"id":38618,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-16","decision":"authorized","decisionDate":"2024-11-19","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-11-19"},"applicationStatusCode":"Authorised"},{"id":277238,"mscId":38620,"mscInfo":{"id":38620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-03","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"},{"id":248328,"mscId":38616,"mscInfo":{"id":38616,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-21","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-02-19","ctMSCsByApplication":[{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":38621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":38617,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":38618,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":38620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":38616,"mscName":"Belgium","reportingStatusCode":"Authorised"}],"businessKey":"SM-3","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":110867,"applicationId":67197,"mscId":38618,"mscName":"Italy","decisionDate":"2026-02-20T15:19:30.201","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":248327,"part1Id":103535,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":110655,"applicationId":67197,"mscId":38616,"mscName":"Belgium","decisionDate":"2026-02-19T15:30:41.946","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":248328,"part1Id":103535,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":110837,"applicationId":67197,"mscId":38620,"mscName":"Netherlands","decisionDate":"2026-02-20T14:08:37.813","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":277238,"part1Id":103535,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":110707,"applicationId":67197,"mscId":38617,"mscName":"Germany","decisionDate":"2026-02-20T08:51:12.22","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":248331,"part1Id":103535,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":110943,"applicationId":67197,"mscId":38621,"mscName":"Poland","decisionDate":"2026-02-22T21:58:41.833","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":248332,"part1Id":103535,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":111037,"applicationId":67197,"mscId":38619,"mscName":"Spain","decisionDate":"2026-02-23T12:27:44.117","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":248329,"part1Id":103535,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":82617,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2026-04-23","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":298895,"mscId":38619,"mscInfo":{"id":38619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-05-08","decision":"authorized","decisionDate":"2024-11-12","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-11-12"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-05-08","ctMSCsByApplication":[{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":123054,"applicationId":82617,"mscId":38619,"mscName":"Spain","decisionDate":"2026-05-08T13:27:18.518","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":298895,"part1Id":126496,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":84312,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2026-05-15","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-07-20"},"partIIInfo":[{"id":304742,"mscId":38619,"mscInfo":{"id":38619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-18","decision":"authorized","decisionDate":"2024-11-12","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2024-11-12"},"applicationStatusCode":"Authorised"},{"id":304744,"mscId":38617,"mscInfo":{"id":38617,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-26","decision":"authorized","decisionDate":"2024-11-13","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-11-13"},"applicationStatusCode":"Authorised"},{"id":304740,"mscId":38618,"mscInfo":{"id":38618,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-16","decision":"authorized","decisionDate":"2024-11-19","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-11-19"},"applicationStatusCode":"Authorised"},{"id":304745,"mscId":38621,"mscInfo":{"id":38621,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-29","decision":"authorized","decisionDate":"2024-12-09","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2024-12-09"},"applicationStatusCode":"Authorised"},{"id":304743,"mscId":38620,"mscInfo":{"id":38620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-23","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"},{"id":304741,"mscId":38616,"mscInfo":{"id":38616,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-07-02","decision":"authorized","decisionDate":"2024-10-30","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2024-10-30"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-07-21","ctMSCsByApplication":[{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":38617,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":38618,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":38621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":38620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":38616,"mscName":"Belgium","reportingStatusCode":"Authorised"}],"businessKey":"SM-6","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":134216,"applicationId":84312,"mscId":38617,"mscName":"Germany","decisionDate":"2026-07-23T10:09:05.65","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":304744,"part1Id":129053,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":134418,"applicationId":84312,"mscId":38621,"mscName":"Poland","decisionDate":"2026-07-24T10:39:26.429","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":304745,"part1Id":129053,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":134125,"applicationId":84312,"mscId":38618,"mscName":"Italy","decisionDate":"2026-07-22T16:05:21.223","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":304740,"part1Id":129053,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":133814,"applicationId":84312,"mscId":38620,"mscName":"Netherlands","decisionDate":"2026-07-21T10:49:34.885","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":304743,"part1Id":129053,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":134394,"applicationId":84312,"mscId":38619,"mscName":"Spain","decisionDate":"2026-07-24T10:02:10.884","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":304742,"part1Id":129053,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":134124,"applicationId":84312,"mscId":38616,"mscName":"Belgium","decisionDate":"2026-07-22T16:05:17.727","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":304741,"part1Id":129053,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":91709,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515909-26-00","trialStatus":"Authorised","submissionDate":"2026-08-11","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-07-20"},"partIIInfo":[],"decisionDate":"2026-08-11","ctMSCsByApplication":[{"id":38619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":38617,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":38618,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":38621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":38620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":38616,"mscName":"Belgium","reportingStatusCode":"Authorised"}],"businessKey":"NSM-3","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":137070,"applicationId":91709,"mscId":38619,"mscName":"Spain","decisionDate":"2026-08-11T11:08:58.874","decision":"authorized","eventType":"decision","part1Id":139956,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":137070,"applicationId":91709,"mscId":38617,"mscName":"Germany","decisionDate":"2026-08-11T11:08:58.874","decision":"authorized","eventType":"decision","part1Id":139956,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":137070,"applicationId":91709,"mscId":38618,"mscName":"Italy","decisionDate":"2026-08-11T11:08:58.874","decision":"authorized","eventType":"decision","part1Id":139956,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":137070,"applicationId":91709,"mscId":38621,"mscName":"Poland","decisionDate":"2026-08-11T11:08:58.874","decision":"authorized","eventType":"decision","part1Id":139956,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":137070,"applicationId":91709,"mscId":38620,"mscName":"Netherlands","decisionDate":"2026-08-11T11:08:58.874","decision":"authorized","eventType":"decision","part1Id":139956,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true},{"id":137070,"applicationId":91709,"mscId":38616,"mscName":"Belgium","decisionDate":"2026-08-11T11:08:58.874","decision":"authorized","eventType":"decision","part1Id":139956,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Netherlands","mscId":38620,"firstDecisionDate":"2024-10-30T11:32:56.31","lastDecisionDate":"2026-07-21T10:49:34.885","mscPublicStatusCode":5},{"mscName":"Poland","mscId":38621,"firstDecisionDate":"2024-12-09T09:21:38.675","lastDecisionDate":"2026-07-24T10:39:26.429","mscPublicStatusCode":5},{"mscName":"Belgium","mscId":38616,"firstDecisionDate":"2024-10-30T14:44:09.822","lastDecisionDate":"2026-07-22T16:05:17.727","mscPublicStatusCode":5},{"mscName":"Italy","mscId":38618,"firstDecisionDate":"2024-11-19T00:00:00","lastDecisionDate":"2026-07-22T16:05:21.223","mscPublicStatusCode":5},{"mscName":"Germany","mscId":38617,"firstDecisionDate":"2024-11-13T09:16:40.394","lastDecisionDate":"2026-07-23T10:09:05.65","mscPublicStatusCode":5},{"mscName":"Spain","mscId":38619,"firstDecisionDate":"2024-11-12T08:18:36.668","lastDecisionDate":"2026-07-24T10:02:10.884","mscPublicStatusCode":5}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2020-005833-34"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":38616,"mscName":"Belgium","events":[{"notificationType":"START_OF_TRIAL","date":"2023-07-26"},{"notificationType":"START_OF_RECRUITMENT","date":"2023-10-03"},{"notificationType":"END_OF_RECRUITMENT","date":"2024-02-14"}]},{"mscId":38617,"mscName":"Germany","events":[{"notificationType":"START_OF_TRIAL","date":"2023-05-31"},{"notificationType":"START_OF_RECRUITMENT","date":"2023-07-04"},{"notificationType":"END_OF_RECRUITMENT","date":"2024-02-14"}]},{"mscId":38618,"mscName":"Italy","events":[{"notificationType":"START_OF_TRIAL","date":"2023-11-07"},{"notificationType":"START_OF_RECRUITMENT","date":"2023-11-08"},{"notificationType":"END_OF_RECRUITMENT","date":"2024-02-14"}]},{"mscId":38619,"mscName":"Spain","events":[{"notificationType":"START_OF_TRIAL","date":"2022-01-27"},{"notificationType":"START_OF_RECRUITMENT","date":"2022-02-07"},{"notificationType":"END_OF_RECRUITMENT","date":"2024-02-14"}]},{"mscId":38620,"mscName":"Netherlands","events":[{"notificationType":"START_OF_TRIAL","date":"2022-01-26"},{"notificationType":"START_OF_RECRUITMENT","date":"2022-02-09"},{"notificationType":"END_OF_RECRUITMENT","date":"2024-02-14"}]},{"mscId":38621,"mscName":"Poland","events":[{"notificationType":"START_OF_TRIAL","date":"2023-01-10"},{"notificationType":"START_OF_RECRUITMENT","date":"2023-01-30"},{"notificationType":"END_OF_RECRUITMENT","date":"2024-02-14"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"K1_Recruitment arrangements_placeholder_san","uuid":"af5aa90d-99a6-4824-a808-450f583808e3","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304742,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main Part B_red_san","uuid":"1567b9e8-2b5a-4429-86fc-cc523407e209","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":304742,"manualVersion":"9.0ESP1.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Main OLE_red_san","uuid":"2dafabc1-dfd1-43c8-a345-359908f87b74","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":304742,"manualVersion":"6.0ESP1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pregnant Partner_clean_san","uuid":"7125255b-2e2a-495a-a1db-31ecabb25a0e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":304742,"manualVersion":"V2.0ESP1.0","systemVersion":"1"},{"title":"L1_Main OLE ICF_CL","uuid":"e3e83d2f-599e-4643-9cb8-a3c22b9841ec","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304742,"manualVersion":"6.0ESP1.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements_blank","uuid":"f9406306-0ebb-463f-bce2-920cfd40d15e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304744,"manualVersion":"N/A","systemVersion":"1"},{"title":"K1_Recruitment arrangement","uuid":"5255b14a-b0f6-4f65-9c0f-c3fe102bc495","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304744,"manualVersion":"v1.1","systemVersion":"2"},{"title":"L1_SIS and ICF_Main OLE_red_san","uuid":"cbc3d429-fd65-4939-a7aa-8fa0d4505a33","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":304744,"manualVersion":"6DEU(de)1","systemVersion":"6"},{"title":"L1_SIS and ICF_Main Part B_red_san","uuid":"d7a0e986-f78d-4021-b4b3-de340cf4e564","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":304744,"manualVersion":"9DEU(de)1","systemVersion":"6"},{"title":"L1_SIS and ICF_Pregnancy FU_san","uuid":"1e63606d-33ae-4847-bc1a-5625b8cdeb0f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":304744,"manualVersion":"V2DEU(de)1","systemVersion":"1"},{"title":"K1_Blank Recruitment arrangements_IT","uuid":"ded52bb4-64cb-4359-ae85-53e948ae73ee","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304740,"manualVersion":"NA","systemVersion":"2"},{"title":"L1_SIS and ICF_Main Part B_Red","uuid":"7c2f004b-e33d-48c1-853f-11b4eee7ce37","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":304740,"manualVersion":"V9.0ITA1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Main OLE_Red","uuid":"302b65c1-260e-461f-acd6-f21f50f8ea64","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":304740,"manualVersion":"V6.0ITA1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_PP_Red","uuid":"6512c753-8df1-4a2d-a7c2-415516bd98ae","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":304740,"manualVersion":"V2.0ITA1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main Privacy","uuid":"5faf278b-b62c-4aff-9b2b-8a3f63f084f8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":304740,"manualVersion":"V1.0ITA1.0","systemVersion":"1"},{"title":"K1_Blank doc for CTIS placeholders for transitional trial_san","uuid":"a4a99c95-3996-494b-b11b-20b756e79109","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304745,"manualVersion":"1.1","systemVersion":"1"},{"title":"K1_Recruitment Arrangements_ placeholder_san","uuid":"588d1e95-f70f-4dca-b774-c46a21e06377","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304745,"manualVersion":"1.1","systemVersion":"1"},{"title":"L1_SIS and ICF_Main OLE_PL_redacted","uuid":"ef77665c-d1ab-4223-9707-3f2b5e583ebc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":304745,"manualVersion":"V6.0POL1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Main Part B_PL_redacted","uuid":"bc734db5-805a-4034-93c9-21f02ece1b85","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":304745,"manualVersion":"V9.0POL1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pregnant Partner_PL_san","uuid":"078d153b-1b5b-4104-b80c-24f5d3743e60","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":304745,"manualVersion":"V2.0POL1.0","systemVersion":"1"},{"title":"K1_AL-DES-01_Recruitment arrangements and consent procedures_Recruitment is closed","uuid":"048347d2-aced-4525-beaa-b28e6229e215","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304743,"manualVersion":"1.1","systemVersion":"2"},{"title":"L1_AL-DES-01_Main ICF_OLE_red-san","uuid":"5950059b-cdf8-4bfa-b1fc-68567a7f7595","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304743,"manualVersion":"6.0NLD1.0","systemVersion":"5"},{"title":"L1_ AL-DES-01_Pregnant Partner ICF_red-san","uuid":"c829e959-8973-42ce-8a30-13f8c1e05866","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304743,"manualVersion":"V2.0NLD2.0","systemVersion":"1"},{"title":"L1_AL-DES-01_Main ICF_Part B_red-san","uuid":"4688927c-871b-43e2-ba44-1184b810a52f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304743,"manualVersion":"9.0NLD1.0","systemVersion":"6"},{"title":"K1_ Recruitment arrangements_BE_San","uuid":"be673b4e-229e-4ab8-ba62-7b2e3f47a8e8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"1.1","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnant Participant _Dutch_San","uuid":"a72624c4-5384-48ac-9f3c-ad6af46633fd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"V2.0BEL3.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnant Participant _English_San","uuid":"18a04ef5-2ba2-4f07-b953-c346d0d3f022","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"V2.0BEL3.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnant Partner ICF _Dutch_San","uuid":"3443ccdf-b237-46a5-b466-56fa21f9ef9d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"V2.0BEL3.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnant Partner_English_San","uuid":"11b08de1-2524-4cca-a06c-9604980527f6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"V2.0BEL3.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main ICF_English_redacted","uuid":"cd99c2bb-c15e-4cd5-8db9-3f12dfb23d06","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"9.0BEL1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Main ICF_Dutch_redacted","uuid":"72e137bb-3f04-4cb1-b819-21dc3ae26697","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"9.0BEL1.0","systemVersion":"4"},{"title":"L1_SIS and ICF_OLE ICF_English_redacted","uuid":"1c5d6e79-fc60-4b01-85fc-414b4c65cfe1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"5.0BEL1.0","systemVersion":"3"},{"title":"L1_SIS and ICF_OLE ICF_Dutch_redacted","uuid":"fcd05451-1603-4be0-b1e9-4c3269469292","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":304741,"manualVersion":"5.0BEL1.0","systemVersion":"3"},{"title":"D1_Protocol_2024-515909-26-00_red san","uuid":"d22424a4-0d24-41c4-85a1-4f86b5b381b3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"8.0","systemVersion":"3"},{"title":"D4_Patient facing documents_Blank doc for CTIS placeholders for copyrighted material_san","uuid":"85ede3d4-11a4-475c-bbcf-4e74f6a6daf0","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"1.0","systemVersion":"2"},{"title":"D1_Protocol Full Synopsis_2024-515909-26-00_EN_red-san","uuid":"aee64b5d-954f-4194-90e2-0ed8ee1155fb","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"8.0","systemVersion":"3"},{"title":"D1_Protocol Full synopsis_2024-515909-26-00_IT_red-san","uuid":"8c298818-ea5c-4091-801c-8384b63096a8","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"8.0","systemVersion":"4"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_EN","uuid":"e9b790f3-8122-40e9-9950-ead505bd5001","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_ES","uuid":"74e5e346-0d8a-42b7-b4a3-1c00b8c6cc44","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_fr-BE","uuid":"d5797f35-ba32-4127-8d79-791fbf448228","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_nl-BE","uuid":"fcc6620f-70c3-402b-bb14-ea35ffb584cb","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_PL","uuid":"fea1dd08-0edc-4a0b-9498-87b6458527b1","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_NL","uuid":"ef3edbcf-ce4a-43af-83ef-1e0bafc796ad","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"3"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_IT","uuid":"ed618f82-e0b4-4017-beb1-9d7027b1e217","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_de-BE","uuid":"967a19b6-a537-4a0c-b327-afb2c0b333ca","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_2024-515909-26-00_DE","uuid":"1e93901e-907b-4c19-b13b-f22ddb979136","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":139956,"manualVersion":"2.0","systemVersion":"2"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}